|
G |
A2M |
alpha-2-macroglobulin |
increases expression |
ISO |
Sirolimus results in increased expression of A2M mRNA |
CTD |
PMID:21865292 |
|
NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
EXP ISO |
[Sirolimus co-treated with Cyclosporine] results in decreased expression of ABCA1 protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein Sirolimus results in increased expression of ABCA1 mRNA |
CTD |
PMID:17016853 PMID:21865292 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects metabolic processing affects transport |
EXP |
ABCB1 protein affects the metabolism of Sirolimus ABCB1 protein affects the transport of Sirolimus |
CTD |
PMID:15707415 PMID:15760093 PMID:15964407 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Sirolimus results in decreased expression of ABCC2 mRNA |
CTD |
PMID:11589784 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC8 |
ATP binding cassette subfamily C member 8 |
decreases expression |
ISO |
Sirolimus results in decreased expression of ABCC8 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr11:17,392,498...17,476,845
Ensembl chr11:17,392,498...17,476,894
|
|
G |
ABCD3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
EXP |
Sirolimus results in decreased expression of ABCD3 protein |
CTD |
PMID:36214828 |
|
NCBI chr 1:94,385,131...94,518,663
Ensembl chr 1:94,418,389...94,518,666
|
|
G |
ABTB3 |
ankyrin repeat and BTB domain containing 3 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of ABTB3 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr12:107,318,434...107,659,642
Ensembl chr12:107,318,421...107,659,642
|
|
G |
ACADL |
acyl-CoA dehydrogenase long chain |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 2:210,187,923...210,225,447
Ensembl chr 2:210,187,126...210,225,447
|
|
G |
ACADM |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Sirolimus results in decreased expression of ACE2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACER2 |
alkaline ceramidase 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 9:19,409,009...19,452,505
Ensembl chr 9:19,409,009...19,452,505
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP ISO |
[Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:17908691 PMID:35405287 |
|
NCBI chr10:88,935,074...88,991,337
Ensembl chr10:88,934,822...88,991,339
|
|
G |
ACTB |
actin beta |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of ACTB mRNA [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA |
CTD |
PMID:7503980 |
|
NCBI chr 7:5,527,148...5,530,601
Ensembl chr 7:5,526,409...5,563,902
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr 1:230,702,523...230,745,583
Ensembl chr 1:230,690,776...230,745,576
|
|
G |
AIFM1 |
apoptosis inducing factor mitochondria associated 1 |
decreases expression multiple interactions |
ISO EXP |
Sirolimus results in decreased expression of AIFM1 protein [7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of AIFM1 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of AIFM1 protein] |
CTD |
PMID:15767555 PMID:16497721 |
|
NCBI chr X:130,129,362...130,165,841
Ensembl chr X:130,124,666...130,165,879
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation affects phosphorylation increases phosphorylation |
EXP ISO |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased phosphorylation of AKT1 protein; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Cisplatin inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Tretinoin results in increased phosphorylation of AKT1 protein] [Sirolimus co-treated with Resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [Resveratrol results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein] Sirolimus results in decreased phosphorylation of AKT1 protein Sirolimus affects the phosphorylation of AKT1 protein [Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein; Sirolimus results in increased phosphorylation of AKT1 protein resveratrol inhibits the reaction [Sirolimus results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]] |
CTD |
PMID:15806154 PMID:18495876 PMID:18622747 PMID:19176369 PMID:21092744 PMID:21976531 PMID:23000059 PMID:24299490 PMID:24304514 PMID:24392034 PMID:25597859 PMID:25758096 PMID:26282490 PMID:26369790 PMID:28108221 PMID:28342888 PMID:30905858 PMID:31499194 PMID:37290678 More...
|
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AKT1S1 |
AKT1 substrate 1 |
multiple interactions |
ISO |
[Sirolimus co-treated with resveratrol] results in decreased phosphorylation of AKT1S1 protein; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein] [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of AKT1S1 protein |
CTD |
PMID:24304514 |
|
NCBI chr19:49,869,033...49,878,356
Ensembl chr19:49,869,033...49,878,459
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
[Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein; Sirolimus results in increased phosphorylation of and results in increased activity of AKT2 protein |
CTD |
PMID:17908691 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
ALPL |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of ALPL mRNA]] |
CTD |
PMID:33450223 |
|
NCBI chr 1:21,508,984...21,578,410
Ensembl chr 1:21,509,397...21,578,410
|
|
G |
ANGPTL6 |
angiopoietin like 6 |
increases expression |
ISO |
Sirolimus results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr19:10,092,338...10,106,190
Ensembl chr19:10,092,338...10,102,678
|
|
G |
AOPEP |
aminopeptidase O (putative) |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 9:94,726,699...95,150,224
Ensembl chr 9:94,726,604...95,151,793
|
|
G |
APOD |
apolipoprotein D |
affects localization |
EXP |
Sirolimus affects the localization of APOD protein |
CTD |
PMID:28182653 |
|
NCBI chr 3:195,568,705...195,583,940
Ensembl chr 3:195,568,705...195,584,033
|
|
G |
APP |
amyloid beta precursor protein |
decreases expression increases expression |
EXP ISO |
Sirolimus results in decreased expression of APP protein modified form Sirolimus results in increased expression of APP protein modified form |
CTD |
PMID:20542014 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
AQP2 |
aquaporin 2 |
multiple interactions decreases expression |
ISO |
rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of AQP2 protein] |
CTD |
PMID:19656910 |
|
NCBI chr12:49,950,737...49,958,878
Ensembl chr12:49,950,737...49,958,878
|
|
G |
AR |
androgen receptor |
multiple interactions increases activity increases expression |
EXP |
[Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; bicalutamide inhibits the reaction [Sirolimus results in increased activity of AR protein]; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus affects the reaction [Testosterone results in increased expression of AR protein]; Sirolimus promotes the reaction [Dihydrotestosterone affects the expression of AR protein] Sirolimus results in increased expression of AR protein |
CTD |
PMID:18776922 PMID:21036700 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
ASNS |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 7:97,851,677...97,928,441
Ensembl chr 7:97,851,677...97,872,542
|
|
G |
ATF3 |
activating transcription factor 3 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of ATF3 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of ATF4] Sirolimus inhibits the reaction [cadmium acetate results in increased expression of ATF4 protein] |
CTD |
PMID:24057571 PMID:29870746 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions |
EXP |
[Sirolimus co-treated with hydroquinone] results in decreased expression of ATF6 protein |
CTD |
PMID:37148176 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
|
|
G |
ATG4A |
autophagy related 4A cysteine peptidase |
increases expression |
ISO |
Sirolimus results in increased expression of ATG4A mRNA |
CTD |
PMID:21681844 |
|
NCBI chr X:108,088,829...108,154,671
Ensembl chr X:108,091,668...108,154,671
|
|
G |
ATG4B |
autophagy related 4B cysteine peptidase |
increases expression multiple interactions |
ISO EXP |
Sirolimus results in increased expression of ATG4B mRNA Sirolimus inhibits the reaction [ATG4B protein results in increased expression of HK2 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of SLC2A1 protein] |
CTD |
PMID:21681844 PMID:36336208 |
|
NCBI chr 2:241,637,693...241,673,857
Ensembl chr 2:241,637,213...241,673,857
|
|
G |
ATG5 |
autophagy related 5 |
multiple interactions increases expression |
EXP ISO |
[Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [Particulate Matter results in increased expression of ATG5 protein]] [Sirolimus co-treated with cadmium acetate] results in increased expression of ATG5 mRNA; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]]; Sirolimus promotes the reaction [Lipopolysaccharides results in increased expression of ATG5 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]] Sirolimus results in increased expression of ATG5 mRNA; Sirolimus results in increased expression of ATG5 protein |
CTD |
PMID:19682553 PMID:29128638 PMID:29505745 PMID:29781141 PMID:29870746 PMID:30338810 PMID:30611790 PMID:31676321 PMID:33823232 PMID:36639017 PMID:37654027 More...
|
|
NCBI chr 6:106,184,476...106,325,760
Ensembl chr 6:106,045,423...106,325,791
|
|
G |
ATG7 |
autophagy related 7 |
multiple interactions |
EXP |
[Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA |
CTD |
PMID:31676321 |
|
NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
|
|
G |
AURKB |
aurora kinase B |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of AURKB mRNA |
CTD |
PMID:19016759 |
|
NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
|
|
G |
BAD |
BCL2 associated agonist of cell death |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr11:64,269,828...64,284,704
Ensembl chr11:64,269,830...64,284,704
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
affects localization multiple interactions increases expression |
EXP ISO |
Sirolimus affects the localization of BAX protein [Curcumin co-treated with Sirolimus] results in increased expression of BAX; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BAX protein]; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BAX protein]; Sirolimus promotes the reaction [hydroquinone results in increased expression of BAX protein] Sirolimus results in increased expression of BAX protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of BAX protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [sophoricoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] Sirolimus results in increased expression of BAX mRNA; Sirolimus results in increased expression of BAX protein |
CTD |
PMID:11602639 PMID:15782132 PMID:19373661 PMID:19922502 PMID:29054700 PMID:30905858 PMID:33684387 PMID:35134463 PMID:37148176 PMID:37290678 PMID:37741537 PMID:38237716 More...
|
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BBC3 |
BCL2 binding component 3 |
multiple interactions |
EXP |
[[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] |
CTD |
PMID:19560264 PMID:20686837 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions decreases expression affects expression |
EXP ISO |
[Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BCL2 protein]; Sirolimus inhibits the reaction [Colistin results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BCL2 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2 protein]; Sirolimus promotes the reaction [Artesunate results in decreased expression of BCL2 protein]; Sirolimus promotes the reaction [Ethanol results in increased expression of BCL2 protein] Sirolimus results in decreased expression of BCL2 mRNA; Sirolimus results in decreased expression of BCL2 protein [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; Sirolimus inhibits the reaction [Particulate Matter results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sirolimus inhibits the reaction [sophoricoside inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]] Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [lactacystin results in decreased expression of BCL2 protein]; Sirolimus inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] Sirolimus affects the expression of BCL2 protein |
CTD |
PMID:11355896 PMID:15571967 PMID:18640276 PMID:19373661 PMID:19764996 PMID:19815708 PMID:21410490 PMID:29054700 PMID:30905858 PMID:33002460 PMID:33823232 PMID:35134463 PMID:35378205 PMID:37290678 PMID:37741537 PMID:38237716 More...
|
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions decreases expression increases expression |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of BCL2L1 protein; Sirolimus inhibits the reaction [Colistin results in decreased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein]; Sirolimus inhibits the reaction [rebamipide results in increased expression of BCL2L1 protein] Sirolimus results in decreased expression of BCL2L1 protein [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of BCL2L1 protein] Sirolimus results in decreased expression of BCL2L1 mRNA; Sirolimus results in decreased expression of BCL2L1 protein Sirolimus results in increased expression of BCL2L1 mRNA; Sirolimus results in increased expression of BCL2L1 protein |
CTD |
PMID:11355896 PMID:15767555 PMID:15782132 PMID:18097008 PMID:18789402 PMID:19922502 PMID:21681844 PMID:29054700 PMID:35378205 More...
|
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BCL2L11 |
BCL2 like 11 |
multiple interactions increases expression decreases expression |
EXP ISO |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; Sirolimus inhibits the reaction [rebamipide results in decreased expression of BCL2L11 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of BCL2L11 mRNA] Sirolimus results in increased expression of BCL2L11 protein Sirolimus results in decreased expression of BCL2L11 protein |
CTD |
PMID:18097008 PMID:21092744 PMID:29054700 |
|
NCBI chr 2:111,120,914...111,168,445
Ensembl chr 2:111,119,378...111,168,444
|
|
G |
BDNF |
brain derived neurotrophic factor |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein]; Sirolimus inhibits the reaction [Creatine results in increased expression of BDNF protein]; Sirolimus inhibits the reaction [Ketamine results in increased expression of BDNF protein] |
CTD |
PMID:17209049 PMID:33022268 |
|
NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058
|
|
G |
BECN1 |
beclin 1 |
multiple interactions increases expression |
EXP ISO |
[Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; Sirolimus inhibits the reaction [Ethanol results in increased degradation of BECN1 protein]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of BECN1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [Caffeine results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein] Sirolimus results in increased expression of BECN1 protein Sirolimus results in increased expression of BECN1 mRNA; Sirolimus results in increased expression of BECN1 protein [Sirolimus co-treated with cadmium acetate] results in increased expression of BECN1 mRNA; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; Sirolimus promotes the reaction [T-2 Toxin results in increased expression of BECN1 mRNA] Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [phenanthrene results in decreased expression of BECN1 mRNA]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus promotes the reaction [Trichloroethylene results in increased expression of BECN1 protein] |
CTD |
PMID:20358864 PMID:21410490 PMID:26648565 PMID:26825372 PMID:27107786 PMID:28025121 PMID:28888487 PMID:29505745 PMID:29518472 PMID:29870746 PMID:30555576 PMID:30611790 PMID:30629952 PMID:30905858 PMID:31676321 PMID:32306690 PMID:32430275 PMID:32645460 PMID:33823232 PMID:34453960 PMID:34536393 PMID:35134463 PMID:36849104 More...
|
|
NCBI chr17:42,810,132...42,824,282
Ensembl chr17:42,810,134...42,833,350
|
|
G |
BGLAP |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of BGLAP mRNA]] |
CTD |
PMID:23111315 PMID:33450223 |
|
NCBI chr 1:156,242,184...156,243,317
Ensembl chr 1:156,242,184...156,243,317
|
|
G |
BID |
BH3 interacting domain death agonist |
multiple interactions decreases expression increases expression |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of BID protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein Sirolimus results in decreased expression of BID protein Sirolimus results in increased expression of BID mRNA; Sirolimus results in increased expression of BID protein |
CTD |
PMID:15767555 PMID:18097008 PMID:19922502 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
BIRC2 |
baculoviral IAP repeat containing 2 |
multiple interactions affects localization increases expression |
EXP ISO |
Sirolimus inhibits the reaction [Doxorubicin results in increased expression of BIRC2 protein] Sirolimus affects the localization of BIRC2 protein Sirolimus results in increased expression of BIRC2 protein |
CTD |
PMID:15571967 PMID:21357504 |
|
NCBI chr11:102,347,214...102,378,670
Ensembl chr11:102,347,211...102,378,670
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
multiple interactions decreases expression |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BIRC5 mRNA; Sirolimus inhibits the reaction [N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide results in increased expression of and affects the localization of BIRC5 protein]; Sirolimus promotes the reaction [Tamoxifen results in decreased expression of BIRC5 protein] Sirolimus results in decreased expression of BIRC5 protein |
CTD |
PMID:19016759 PMID:19931998 PMID:21601561 PMID:24444656 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BMP2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr20:6,767,686...6,780,246
Ensembl chr20:6,767,686...6,780,246
|
|
G |
BNIP3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr10:131,967,684...131,981,923
Ensembl chr10:131,967,684...131,981,967
|
|
G |
BTC |
betacellulin |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein] |
CTD |
PMID:19105244 |
|
NCBI chr 4:74,744,759...74,794,523
Ensembl chr 4:74,744,759...74,794,523
|
|
G |
BTK |
Bruton tyrosine kinase |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr X:101,349,450...101,390,796
Ensembl chr X:101,349,338...101,390,796
|
|
G |
BUB1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 2:110,637,528...110,678,063
Ensembl chr 2:110,637,528...110,678,063
|
|
G |
BUB1B |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of BUB1B mRNA |
CTD |
PMID:19016759 |
|
NCBI chr15:40,161,069...40,221,123
Ensembl chr15:40,161,023...40,221,123
|
|
G |
C1QA |
complement C1q A chain |
decreases expression |
ISO |
Sirolimus results in decreased expression of C1QA mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:22,636,463...22,639,678
Ensembl chr 1:22,635,077...22,639,678
|
|
G |
C1QC |
complement C1q C chain |
decreases expression |
ISO |
Sirolimus results in decreased expression of C1QC mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:22,643,633...22,648,108
Ensembl chr 1:22,643,014...22,648,110
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Sirolimus results in decreased expression of C3 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
|
|
G |
CALD1 |
caldesmon 1 |
multiple interactions increases expression |
EXP |
[Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of CALD1 protein Sirolimus results in increased expression of CALD1 protein |
CTD |
PMID:17908691 |
|
NCBI chr 7:134,745,467...134,970,729
Ensembl chr 7:134,744,252...134,970,729
|
|
G |
CAMK2A |
calcium/calmodulin dependent protein kinase II alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:21933187 |
|
NCBI chr 5:150,219,491...150,290,130
Ensembl chr 5:150,219,491...150,290,093
|
|
G |
CAPN1 |
calpain 1 |
decreases activity |
ISO |
Sirolimus results in decreased activity of CAPN1 protein |
CTD |
PMID:21357504 |
|
NCBI chr11:65,181,373...65,212,006
Ensembl chr11:65,180,566...65,212,006
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP1 protein] Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of CASP1 protein]; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of CASP1 protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of CASP1 mRNA] |
CTD |
PMID:30205151 PMID:31586597 PMID:35405287 PMID:36849104 PMID:37654027 PMID:38237716 More...
|
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP12 |
caspase 12 (gene/pseudogene) |
decreases cleavage multiple interactions |
ISO |
Sirolimus results in decreased cleavage of CASP12 protein Sirolimus inhibits the reaction [cadmium acetate results in increased expression of CASP12 protein] |
CTD |
PMID:20511674 PMID:29870746 |
|
NCBI chr11:104,883,286...104,898,460
Ensembl chr11:104,885,718...104,898,670
|
|
G |
CASP2 |
caspase 2 |
multiple interactions |
EXP |
[Boc-D-FMK co-treated with Sirolimus] results in increased cleavage of CASP2 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP2 protein] |
CTD |
PMID:15767555 |
|
NCBI chr 7:143,288,351...143,307,696
Ensembl chr 7:143,288,215...143,307,696
|
|
G |
CASP3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression decreases activity |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CASP3 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP3 protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CASP3 mRNA]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Colistin results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CASP3 mRNA] Sirolimus results in increased activity of CASP3 protein Sirolimus results in increased cleavage of CASP3 protein Sirolimus results in decreased activity of CASP3 protein Sirolimus results in increased expression of CASP3 mRNA; Sirolimus results in increased expression of CASP3 protein [Sirolimus co-treated with Resveratrol] results in increased cleavage of CASP3 protein; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form]; Sirolimus promotes the reaction [decamethrin results in increased cleavage of CASP3 protein]; Sirolimus results in decreased cleavage of and results in decreased activity of CASP3 protein Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Sirolimus inhibits the reaction [gelsenicine results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Cadmium results in increased cleavage of CASP3 protein] Sirolimus results in increased expression of CASP3 protein modified form |
CTD |
PMID:14502240 PMID:15571967 PMID:15753396 PMID:15767555 PMID:15782132 PMID:15878982 PMID:16497721 PMID:18058806 PMID:18097008 PMID:19373661 PMID:19682553 PMID:19764996 PMID:20031680 PMID:20358864 PMID:21357504 PMID:21410490 PMID:21681844 PMID:24299490 PMID:24304514 PMID:26588882 PMID:26825372 PMID:28342888 PMID:29111403 PMID:30030080 PMID:30236763 PMID:30629952 PMID:31676321 PMID:32802178 PMID:33002460 PMID:33684387 PMID:33823232 PMID:34374793 PMID:35175747 PMID:35378205 PMID:35588915 PMID:38237716 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CASP7 |
caspase 7 |
multiple interactions decreases activity |
EXP ISO |
[Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP7 protein Sirolimus results in decreased activity of CASP7 protein |
CTD |
PMID:15753396 PMID:19373661 PMID:20031680 |
|
NCBI chr10:113,679,194...113,730,909
Ensembl chr10:113,679,162...113,730,907
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases cleavage |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP8 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP8 protein] Sirolimus results in increased cleavage of CASP8 protein Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]] |
CTD |
PMID:15767555 PMID:17121904 PMID:18058806 PMID:25307878 PMID:28342888 |
|
NCBI chr 2:201,233,463...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CASP9 |
caspase 9 |
multiple interactions decreases activity |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Sirolimus co-treated with Cisplatin] results in increased activity of CASP9 protein; [Sirolimus co-treated with Paclitaxel] results in increased cleavage of CASP9 protein; [tanespimycin co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus inhibits the reaction [Colistin results in increased activity of CASP9 protein]; Sirolimus promotes the reaction [Cisplatin results in increased cleavage of CASP9 protein] Sirolimus results in decreased activity of CASP9 protein [Swainsonine co-treated with Sirolimus] results in increased cleavage of CASP9 protein; Sirolimus inhibits the reaction [Staurosporine results in increased cleavage of CASP9 protein] Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]] |
CTD |
PMID:15753396 PMID:15767555 PMID:16497721 PMID:17121904 PMID:18058806 PMID:18097008 PMID:19373661 PMID:20138251 PMID:28342888 PMID:33186601 PMID:35378205 More...
|
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
increases expression |
ISO |
Sirolimus results in increased expression of CAT protein |
CTD |
PMID:30905858 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CAV3 |
caveolin 3 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 3:8,733,802...8,746,758
Ensembl chr 3:8,733,802...8,841,808
|
|
G |
CCN2 |
cellular communication network factor 2 |
increases expression |
ISO |
Sirolimus results in increased expression of CCN2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCNA2 |
cyclin A2 |
multiple interactions decreases expression |
EXP ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CCNA2 mRNA Sirolimus results in decreased expression of CCNA2; Sirolimus results in decreased expression of CCNA2 protein |
CTD |
PMID:7503980 PMID:8419408 PMID:19016759 PMID:19505958 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCNB2 |
cyclin B2 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr15:59,105,146...59,125,045
Ensembl chr15:59,105,126...59,125,045
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions increases degradation increases expression decreases expression |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Sirolimus results in increased expression of CCND1 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with Sirolimus] results in decreased expression of CCND1; [3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CCND1 protein; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus co-treated with Letrozole] results in decreased expression of CCND1 protein; [Sirolimus co-treated with tanespimycin] results in decreased expression of CCND1 protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of CCND1 protein] Sirolimus results in increased degradation of CCND1 protein Sirolimus inhibits the reaction [BTC protein results in increased expression of CCND1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein] |
CTD |
PMID:7532117 PMID:15753396 PMID:15767555 PMID:17121904 PMID:19105244 PMID:19505958 PMID:19661225 PMID:20054642 PMID:23006739 PMID:36640941 More...
|
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND2 |
cyclin D2 |
multiple interactions decreases expression |
EXP ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA] Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] Sirolimus results in decreased expression of CCND2 protein |
CTD |
PMID:15070696 PMID:15778701 PMID:17510244 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CCND3 |
cyclin D3 |
multiple interactions decreases stability decreases expression |
EXP ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA] Sirolimus results in decreased stability of CCND3 mRNA Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein] Sirolimus results in decreased expression of CCND3 mRNA; Sirolimus results in decreased expression of CCND3 protein |
CTD |
PMID:10849422 PMID:12393642 PMID:15070696 PMID:15778701 PMID:15882288 |
|
NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CCNE1 |
cyclin E1 |
multiple interactions increases expression |
EXP |
Curcumin inhibits the reaction [Sirolimus results in increased expression of CCNE1 protein] |
CTD |
PMID:36640941 |
|
NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312
|
|
G |
CCNE2 |
cyclin E2 |
multiple interactions |
EXP |
[Fulvestrant co-treated with Sirolimus] results in decreased expression of CCNE2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA] |
CTD |
PMID:19016759 PMID:27542212 |
|
NCBI chr 8:94,880,224...94,896,693
Ensembl chr 8:94,879,770...94,896,678
|
|
G |
CCNG2 |
cyclin G2 |
multiple interactions increases expression |
EXP |
[cotylenin A co-treated with Sirolimus] results in increased expression of CCNG2 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA] Sirolimus results in increased expression of CCNG2 mRNA |
CTD |
PMID:18754885 PMID:21245298 PMID:24356939 PMID:27542212 |
|
NCBI chr 4:77,157,207...77,170,060
Ensembl chr 4:77,157,207...77,433,388
|
|
G |
CCNI |
cyclin I |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 4:77,047,155...77,075,989
Ensembl chr 4:77,047,155...77,076,309
|
|
G |
CD36 |
CD36 molecule (CD36 blood group) |
affects expression multiple interactions |
EXP |
Sirolimus affects the expression of CD36 protein Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of CD36 mRNA] |
CTD |
PMID:17016853 PMID:19640849 |
|
NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277
|
|
G |
CD38 |
CD38 molecule |
multiple interactions |
ISO |
CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24238063 PMID:24445604 |
|
NCBI chr 4:15,778,328...15,853,232
Ensembl chr 4:15,778,275...15,853,232
|
|
G |
CD68 |
CD68 molecule |
decreases expression |
EXP ISO |
Sirolimus results in decreased expression of CD68 mRNA |
CTD |
PMID:17016853 PMID:21865292 |
|
NCBI chr17:7,579,638...7,582,111
Ensembl chr17:7,579,491...7,582,111
|
|
G |
CD80 |
CD80 molecule |
decreases expression |
ISO |
Sirolimus results in decreased expression of CD80 protein |
CTD |
PMID:12531798 |
|
NCBI chr 3:119,524,293...119,559,614
Ensembl chr 3:119,524,293...119,559,614
|
|
G |
CD84 |
CD84 molecule |
increases expression |
EXP |
Sirolimus results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:160,541,098...160,579,496
Ensembl chr 1:160,541,095...160,579,516
|
|
G |
CD86 |
CD86 molecule |
decreases expression |
ISO |
Sirolimus results in decreased expression of CD86 protein |
CTD |
PMID:12531798 |
|
NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139
|
|
G |
CDC20 |
cell division cycle 20 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of CDC20 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 1:43,358,981...43,363,203
Ensembl chr 1:43,358,981...43,363,203
|
|
G |
CDH1 |
cadherin 1 |
increases expression multiple interactions |
EXP ISO |
Sirolimus results in increased expression of CDH1 protein Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein] NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] |
CTD |
PMID:28624451 PMID:28888487 PMID:30053495 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CDH2 |
cadherin 2 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] |
CTD |
PMID:30053495 |
|
NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
multiple interactions decreases expression decreases activity |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 mRNA; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of CDK1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of CDK1 protein; [fulvestrant co-treated with Sirolimus] results in decreased expression of CDK1 mRNA Sirolimus results in decreased expression of CDK1 Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA] Sirolimus results in decreased activity of CDK1 protein Sirolimus results in decreased expression of CDK1 mRNA; Sirolimus results in decreased expression of CDK1 protein |
CTD |
PMID:7503980 PMID:7532117 PMID:8419408 PMID:11355896 PMID:15767555 PMID:19016759 PMID:19223503 PMID:19922502 More...
|
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CDK2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
EXP ISO |
[Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein Sirolimus results in decreased activity of CDK2 protein [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] |
CTD |
PMID:7532117 PMID:12393642 PMID:12417722 PMID:14979923 PMID:21528311 |
|
NCBI chr12:55,966,830...55,972,789
Ensembl chr12:55,966,781...55,972,789
|
|
G |
CDK4 |
cyclin dependent kinase 4 |
decreases expression |
EXP |
Sirolimus results in decreased expression of CDK4 protein |
CTD |
PMID:22761470 |
|
NCBI chr12:57,747,727...57,752,310
Ensembl chr12:57,747,727...57,756,013
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions increases expression decreases expression |
EXP ISO |
[(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A mRNA; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of CDKN1A protein; [S 1 (combination) co-treated with Sirolimus] results in increased expression of CDKN1A protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; Fluorouracil promotes the reaction [Sirolimus results in increased expression of CDKN1A mRNA]; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A mRNA]; Sirolimus promotes the reaction [(+)-JQ1 compound results in increased expression of CDKN1A protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; Sirolimus promotes the reaction [Fluorouracil results in increased expression of CDKN1A mRNA] Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] Sirolimus results in increased expression of CDKN1A mRNA; Sirolimus results in increased expression of CDKN1A protein Sirolimus results in decreased expression of CDKN1A protein Sirolimus inhibits the reaction [arsenite results in increased expression of CDKN1A protein] |
CTD |
PMID:12417722 PMID:14979923 PMID:17700525 PMID:19105244 PMID:19764996 PMID:21528311 PMID:22561310 PMID:23396362 PMID:25307878 PMID:30555576 PMID:38604309 More...
|
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CDKN1B |
cyclin dependent kinase inhibitor 1B |
multiple interactions decreases degradation increases expression decreases expression |
EXP ISO |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; [Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of CDKN1B mRNA; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of CDKN1B mRNA] Sirolimus results in decreased degradation of CDKN1B protein [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein] Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; Sirolimus inhibits the reaction [BTC protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] Sirolimus results in increased expression of CDKN1B protein Sirolimus results in decreased expression of CDKN1B protein |
CTD |
PMID:12417722 PMID:12565877 PMID:14979923 PMID:15070696 PMID:16455087 PMID:18622747 PMID:19105244 PMID:21092744 PMID:22561310 More...
|
|
NCBI chr12:12,717,368...12,722,369
Ensembl chr12:12,685,498...12,722,369
|
|
G |
CDX2 |
caudal type homeobox 2 |
increases expression |
ISO |
Sirolimus results in increased expression of CDX2 mRNA |
CTD |
PMID:21681844 |
|
NCBI chr13:27,960,918...27,969,315
Ensembl chr13:27,960,918...27,969,315
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
decreases expression |
ISO |
Sirolimus results in decreased expression of CEBPA mRNA |
CTD |
PMID:15358118 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEBPD |
CCAAT enhancer binding protein delta |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Endrin results in increased expression of CEBPD mRNA] |
CTD |
PMID:34801515 |
|
NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164
|
|
G |
CENPX |
centromere protein X |
increases expression |
ISO |
Sirolimus results in increased expression of CENPX mRNA |
CTD |
PMID:11355896 |
|
NCBI chr17:82,018,703...82,022,878
Ensembl chr17:82,018,702...82,024,107
|
|
G |
CFD |
complement factor D |
decreases expression |
ISO |
Sirolimus results in decreased expression of CFD mRNA |
CTD |
PMID:15358118 |
|
NCBI chr19:859,664...863,641
Ensembl chr19:859,453...867,884
|
|
G |
CHRNB3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 8:42,697,366...42,737,407
Ensembl chr 8:42,697,366...42,737,407
|
|
G |
CIDEC |
cell death inducing DFFA like effector c |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of CIDEC mRNA] |
CTD |
PMID:31499194 |
|
NCBI chr 3:9,866,710...9,880,253
Ensembl chr 3:9,866,711...9,880,255
|
|
G |
CKS1B |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
ISO |
Sirolimus results in decreased expression of CKS1B mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 1:154,974,681...154,979,251
Ensembl chr 1:154,974,653...154,979,251
|
|
G |
CLDN7 |
claudin 7 |
increases expression |
ISO |
Sirolimus results in increased expression of CLDN7 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983
|
|
G |
CLEC4A |
C-type lectin domain family 4 member A |
decreases expression |
ISO |
Sirolimus results in decreased expression of CLEC4A mRNA |
CTD |
PMID:21865292 |
|
NCBI chr12:8,102,907...8,138,607
Ensembl chr12:8,123,617...8,138,607
|
|
G |
CLUH |
clustered mitochondria homolog |
increases expression |
EXP |
Sirolimus results in increased expression of CLUH protein |
CTD |
PMID:36214828 |
|
NCBI chr17:2,689,387...2,712,020
Ensembl chr17:2,689,386...2,712,663
|
|
G |
COL1A1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
ISO |
Sirolimus results in decreased expression of COL1A1 mRNA Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein] |
CTD |
PMID:21865292 PMID:35405287 |
|
NCBI chr17:50,184,101...50,201,631
Ensembl chr17:50,184,101...50,201,632
|
|
G |
COL1A2 |
collagen type I alpha 2 chain |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [Acetaldehyde results in increased expression of COL1A2 mRNA] Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10535884 PMID:11343241 |
|
NCBI chr 7:94,394,895...94,431,227
Ensembl chr 7:94,394,895...94,431,227
|
|
G |
COL2A1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Sirolimus results in decreased expression of COL2A1 protein |
CTD |
PMID:34536393 |
|
NCBI chr12:47,972,967...48,006,212
Ensembl chr12:47,972,967...48,004,554
|
|
G |
CP |
ceruloplasmin |
increases expression |
ISO |
Sirolimus results in increased expression of CP mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:149,162,414...149,221,829
Ensembl chr 3:149,162,410...149,221,829
|
|
G |
CPT1B |
carnitine palmitoyltransferase 1B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr22:50,568,861...50,578,612
Ensembl chr22:50,568,861...50,578,465
|
|
G |
CPT2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 1:53,196,824...53,214,197
Ensembl chr 1:53,196,792...53,214,197
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]] |
CTD |
PMID:22363816 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CREBRF |
CREB3 regulatory factor |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CREBRF mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 5:173,056,352...173,139,284
Ensembl chr 5:173,056,352...173,139,284
|
|
G |
CRTC2 |
CREB regulated transcription coactivator 2 |
decreases activity |
EXP |
Sirolimus results in decreased activity of CRTC2 protein |
CTD |
PMID:23440206 |
|
NCBI chr 1:153,947,675...153,958,612
Ensembl chr 1:153,947,669...153,958,615
|
|
G |
CS |
citrate synthase |
multiple interactions |
ISO |
Sirolimus affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein] |
CTD |
PMID:33684387 |
|
NCBI chr12:56,271,699...56,300,330
Ensembl chr12:56,271,699...56,300,391
|
|
G |
CSE1L |
chromosome segregation 1 like |
decreases expression |
ISO |
Sirolimus results in decreased expression of CSE1L mRNA |
CTD |
PMID:11355896 |
|
NCBI chr20:49,046,312...49,096,949
Ensembl chr20:49,046,246...49,096,960
|
|
G |
CSF1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:14502240 |
|
NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]] |
CTD |
PMID:1376361 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30053495 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CTSK |
cathepsin K |
multiple interactions decreases expression |
ISO |
PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased activity of CTSK protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA] Sirolimus results in decreased expression of CTSK mRNA |
CTD |
PMID:26369790 |
|
NCBI chr 1:150,796,208...150,808,260
Ensembl chr 1:150,794,880...150,809,577
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
ISO |
Sirolimus results in decreased expression of CXCL10 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CXCL13 |
C-X-C motif chemokine ligand 13 |
decreases expression |
ISO |
Sirolimus results in decreased expression of CXCL13 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:77,511,753...77,611,834
Ensembl chr 4:77,511,753...77,611,834
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions increases expression |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of CXCL8 mRNA; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA] Sirolimus results in increased expression of CXCL8 mRNA |
CTD |
PMID:17606477 PMID:25307878 PMID:27542212 PMID:29594315 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYBA |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBA protein] |
CTD |
PMID:21195169 |
|
NCBI chr16:88,643,289...88,651,053
Ensembl chr16:88,643,275...88,651,083
|
|
G |
CYBB |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of CYBB protein] |
CTD |
PMID:21195169 |
|
NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
decreases activity |
EXP |
Sirolimus results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
multiple interactions decreases activity |
EXP |
[Cyclosporine co-treated with Sirolimus] results in decreased activity of CYP27A1 protein Sirolimus results in decreased activity of CYP27A1 protein |
CTD |
PMID:17516993 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
decreases expression |
EXP |
Sirolimus results in decreased expression of CYP2A6 protein |
CTD |
PMID:25929522 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
increases expression |
EXP |
Sirolimus results in increased expression of CYP2B6 mRNA |
CTD |
PMID:25929522 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
decreases expression increases expression |
EXP |
Sirolimus results in decreased expression of CYP2C9 protein Sirolimus results in increased expression of CYP2C9 mRNA |
CTD |
PMID:25929522 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [FXN protein affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol]] |
CTD |
PMID:33017621 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
affects metabolic processing |
EXP |
CYP3A4 protein affects the metabolism of Sirolimus; CYP3A4 protein polymorphism affects the metabolism of Sirolimus |
CTD |
PMID:15707415 PMID:15964407 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased expression of DDIT3 protein] Sirolimus inhibits the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein] [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of DDIT3 mRNA; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 mRNA]; Sirolimus inhibits the reaction [arsenite results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [honokiol results in increased expression of DDIT3 protein] |
CTD |
PMID:11145585 PMID:19420259 PMID:21321189 PMID:22215663 PMID:25307878 PMID:29870746 PMID:33550458 PMID:37654027 More...
|
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DDIT4L |
DNA damage inducible transcript 4 like |
decreases expression increases expression |
ISO |
Sirolimus results in decreased expression of DDIT4L mRNA Sirolimus results in increased expression of DDIT4L mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:100,185,870...100,190,468
Ensembl chr 4:100,185,870...100,190,782
|
|
G |
DEPTOR |
DEP domain containing MTOR interacting protein |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 8:119,873,722...120,050,918
Ensembl chr 8:119,873,717...120,050,918
|
|
G |
DIABLO |
diablo IAP-binding mitochondrial protein |
multiple interactions |
EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] affects the localization of DIABLO protein; Boc-D-FMK inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] affects the localization of DIABLO protein] |
CTD |
PMID:15767555 |
|
NCBI chr12:122,207,662...122,227,456
Ensembl chr12:122,207,668...122,226,062
|
|
G |
DLG4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Ketamine results in increased expression of DLG4 protein] |
CTD |
PMID:33022268 |
|
NCBI chr17:7,187,187...7,220,050
Ensembl chr17:7,187,187...7,219,836
|
|
G |
DNAJC6 |
DnaJ heat shock protein family (Hsp40) member C6 |
decreases expression |
ISO |
Sirolimus results in decreased expression of DNAJC6 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:65,264,749...65,415,871
Ensembl chr 1:65,248,219...65,415,871
|
|
G |
DNM1L |
dynamin 1 like |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of DNM1L protein] |
CTD |
PMID:35405287 |
|
NCBI chr12:32,679,301...32,745,650
Ensembl chr12:32,679,200...32,745,650
|
|
G |
DNMT1 |
DNA methyltransferase 1 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of DNMT1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286
|
|
G |
DPYD |
dihydropyrimidine dehydrogenase |
decreases expression |
EXP |
Sirolimus results in decreased expression of DPYD mRNA |
CTD |
PMID:19764996 |
|
NCBI chr 1:97,077,743...97,921,059
Ensembl chr 1:97,077,743...97,995,000
|
|
G |
DUSP10 |
dual specificity phosphatase 10 |
increases expression |
EXP |
Sirolimus results in increased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:221,701,424...221,742,089
Ensembl chr 1:221,701,424...221,742,089
|
|
G |
DUSP15 |
dual specificity phosphatase 15 |
decreases expression |
ISO |
Sirolimus results in decreased expression of DUSP15 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr20:31,845,593...31,870,664
Ensembl chr20:31,847,637...31,870,664
|
|
G |
E2F1 |
E2F transcription factor 1 |
multiple interactions |
EXP ISO |
[TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein |
CTD |
PMID:12417722 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
E2F4 |
E2F transcription factor 4 |
multiple interactions |
EXP |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein] |
CTD |
PMID:12417722 |
|
NCBI chr16:67,192,155...67,198,918
Ensembl chr16:67,192,155...67,198,918
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:12411397 |
|
NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EEF2 |
eukaryotic translation elongation factor 2 |
increases phosphorylation |
EXP |
Sirolimus results in increased phosphorylation of EEF2 protein |
CTD |
PMID:25940091 |
|
NCBI chr19:3,976,056...3,985,463
Ensembl chr19:3,976,056...3,985,463
|
|
G |
EGF |
epidermal growth factor |
multiple interactions decreases activity |
EXP ISO |
Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein] Sirolimus analog results in decreased activity of EGF protein |
CTD |
PMID:12406821 PMID:21187475 |
|
NCBI chr 4:109,912,883...110,013,766
Ensembl chr 4:109,912,883...110,013,766
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
ISO EXP |
[Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of EGFR protein]; Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein |
CTD |
PMID:19151764 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:37654027 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [cadmium acetate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:29870746 |
|
NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516
|
|
G |
EIF4B |
eukaryotic translation initiation factor 4B |
multiple interactions decreases phosphorylation |
ISO EXP |
[resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] results in decreased phosphorylation of EIF4B protein; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein] [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of EIF4B protein Sirolimus results in decreased phosphorylation of EIF4B protein |
CTD |
PMID:21268130 PMID:24304514 PMID:24375594 |
|
NCBI chr12:53,006,456...53,042,215
Ensembl chr12:53,006,282...53,042,215
|
|
G |
EIF4E |
eukaryotic translation initiation factor 4E |
multiple interactions decreases activity increases phosphorylation increases expression |
EXP ISO |
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein] Sirolimus results in decreased activity of EIF4E protein Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4E protein] Sirolimus results in increased phosphorylation of EIF4E protein Sirolimus results in increased expression of EIF4E mRNA |
CTD |
PMID:15757502 PMID:19560264 PMID:26282490 PMID:34453960 |
|
NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation affects phosphorylation |
EXP ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Cisplatin] results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus co-treated with Oxygen deficiency] results in increased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus affects the reaction [Testosterone results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Acetaldehyde results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] Sirolimus inhibits the reaction [AKT1 protein mutant form results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Polystyrenes analog results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein; Tacrolimus inhibits the reaction [Sirolimus results in decreased phosphorylation of and results in increased activity of EIF4EBP1 protein] Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased phosphorylation of EIF4EBP1 protein] Sirolimus affects the phosphorylation of EIF4EBP1 protein |
CTD |
PMID:8599949 PMID:8971030 PMID:11909977 PMID:12411397 PMID:12939469 PMID:14502240 PMID:14673156 PMID:15782132 PMID:15806154 PMID:16255777 PMID:16597595 PMID:16962100 PMID:18021293 PMID:18058806 PMID:18622747 PMID:19478560 PMID:19560264 PMID:19853261 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21321189 PMID:21898527 PMID:21933187 PMID:22869613 PMID:23363784 PMID:24299490 PMID:24375594 PMID:25940091 PMID:32802178 PMID:33609687 PMID:34717917 PMID:36709824 More...
|
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
EIF4G1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358
|
|
G |
EIF4G2 |
eukaryotic translation initiation factor 4 gamma 2 |
increases expression |
EXP |
Sirolimus results in increased expression of EIF4G2 protein |
CTD |
PMID:18491231 |
|
NCBI chr11:10,797,046...10,808,926
Ensembl chr11:10,797,050...10,808,940
|
|
G |
ENO2 |
enolase 2 |
multiple interactions increases expression |
ISO |
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr12:6,914,580...6,923,697
Ensembl chr12:6,913,745...6,923,698
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO EXP |
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein] Sirolimus inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:24898257 PMID:32283200 |
|
NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819
|
|
G |
ERO1A |
endoplasmic reticulum oxidoreductase 1 alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA] |
CTD |
PMID:19420259 |
|
NCBI chr14:52,639,915...52,695,558
Ensembl chr14:52,639,915...52,695,900
|
|
G |
ESPL1 |
extra spindle pole bodies like 1, separase |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of ESPL1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr12:53,268,299...53,293,638
Ensembl chr12:53,268,299...53,293,638
|
|
G |
ESR1 |
estrogen receptor 1 |
increases expression increases phosphorylation |
EXP |
Sirolimus results in increased expression of ESR1 protein Sirolimus results in increased phosphorylation of ESR1 protein |
CTD |
PMID:19016759 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
EVI2A |
ecotropic viral integration site 2A |
increases expression |
EXP |
Sirolimus results in increased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:31,316,410...31,321,622
Ensembl chr17:31,316,410...31,321,749
|
|
G |
EWSR1 |
EWS RNA binding protein 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of EWSR1 protein mutant form |
CTD |
PMID:15782132 |
|
NCBI chr22:29,268,268...29,300,521
Ensembl chr22:29,268,009...29,300,525
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases expression |
ISO |
Sirolimus results in decreased expression of F2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr11:46,719,213...46,739,506
Ensembl chr11:46,719,196...46,739,506
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases activity |
EXP ISO |
Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein] Sirolimus results in increased activity of F3 protein |
CTD |
PMID:19567381 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
FAM200C |
family with sequence similarity 200 member C |
increases expression |
EXP |
Sirolimus results in increased expression of FAM200C mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 5:160,393,148...160,400,054
Ensembl chr 5:160,393,148...160,400,054
|
|
G |
FAS |
Fas cell surface death receptor |
decreases expression |
ISO |
Sirolimus results in decreased expression of FAS mRNA |
CTD |
PMID:15358118 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASLG |
Fas ligand |
decreases secretion |
EXP |
Sirolimus results in decreased secretion of FASLG protein |
CTD |
PMID:11692113 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FAXDC2 |
fatty acid hydroxylase domain containing 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:154,818,492...154,850,603
Ensembl chr 5:154,818,492...154,859,252
|
|
G |
FBLN1 |
fibulin 1 |
increases expression |
ISO |
Sirolimus results in increased expression of FBLN1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr22:45,502,883...45,601,135
Ensembl chr22:45,502,238...45,601,135
|
|
G |
FBXO32 |
F-box protein 32 |
multiple interactions increases expression |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of FBXO32 mRNA; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA] Sirolimus results in increased expression of FBXO32 mRNA |
CTD |
PMID:21245298 PMID:24356939 PMID:25307878 |
|
NCBI chr 8:123,497,889...123,541,206
Ensembl chr 8:123,497,889...123,541,206
|
|
G |
FBXO5 |
F-box protein 5 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of FBXO5 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 6:152,970,535...152,983,579
Ensembl chr 6:152,970,519...152,983,579
|
|
G |
FCGR1A |
Fc gamma receptor Ia |
multiple interactions decreases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Sirolimus results in decreased expression of FCGR1A protein]; arsenic trioxide inhibits the reaction [Sirolimus results in decreased expression of FCGR1A protein] |
CTD |
PMID:25758096 |
|
NCBI chr 1:149,782,694...149,800,609
Ensembl chr 1:149,782,671...149,791,675
|
|
G |
FGB |
fibrinogen beta chain |
decreases expression increases expression |
ISO |
Sirolimus results in decreased expression of FGB mRNA Sirolimus results in increased expression of FGB mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
|
|
G |
FGF1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of FGF1 mRNA; Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:31332898 |
|
NCBI chr 5:142,592,178...142,698,070
Ensembl chr 5:142,592,178...142,698,070
|
|
G |
FGF21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of FGF21 mRNA] |
CTD |
PMID:31499194 |
|
NCBI chr19:48,755,524...48,758,330
Ensembl chr19:48,755,524...48,758,333
|
|
G |
FGF7 |
fibroblast growth factor 7 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr15:49,423,242...49,488,775
Ensembl chr15:49,423,237...49,488,775
|
|
G |
FKBP1A |
FKBP prolyl isomerase 1A |
affects binding multiple interactions |
EXP ISO |
Sirolimus binds to FKBP1A protein [Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Tacrolimus binds to FKBP1A protein] inhibits the reaction [Sirolimus binds to FKBP1A protein] [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein; [Sirolimus binds to FKBP1A protein] which results in increased expression of ACTB mRNA; immunomycin inhibits the reaction [Sirolimus binds to FKBP1A protein] |
CTD |
PMID:7503980 PMID:7532117 PMID:10361256 PMID:12417722 PMID:12531798 PMID:17438408 More...
|
|
NCBI chr20:1,368,978...1,393,054
Ensembl chr20:1,368,977...1,393,164
|
|
G |
FLT3LG |
fms related receptor tyrosine kinase 3 ligand |
decreases activity |
ISO |
Sirolimus results in decreased activity of FLT3LG protein |
CTD |
PMID:12531798 |
|
NCBI chr19:49,474,215...49,486,231
Ensembl chr19:49,474,207...49,486,231
|
|
G |
FOLR1 |
folate receptor alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr11:72,189,709...72,196,323
Ensembl chr11:72,189,558...72,196,323
|
|
G |
FOXM1 |
forkhead box M1 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr12:2,857,680...2,877,174
Ensembl chr12:2,857,680...2,877,174
|
|
G |
FOXO1 |
forkhead box O1 |
increases phosphorylation |
EXP |
Sirolimus results in increased phosphorylation of FOXO1 protein |
CTD |
PMID:16227402 |
|
NCBI chr13:40,555,667...40,666,641
Ensembl chr13:40,555,667...40,666,641
|
|
G |
FOXO3 |
forkhead box O3 |
multiple interactions increases phosphorylation |
EXP |
[Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of BCL2L11 protein; [Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]] which results in increased expression of CDKN1B protein; Cisplatin inhibits the reaction [[Sirolimus results in increased phosphorylation of AKT1 protein] which results in increased phosphorylation of FOXO3 protein]; Sirolimus promotes the reaction [Cisplatin results in increased expression of and results in increased localization of and results in increased activity of FOXO3 protein]; Sirolimus results in decreased degradation of and results in increased phosphorylation of FOXO3 protein |
CTD |
PMID:21092744 |
|
NCBI chr 6:108,559,825...108,684,774
Ensembl chr 6:108,559,835...108,684,774
|
|
G |
FOXP1 |
forkhead box P1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of FOXP1 protein |
CTD |
PMID:25663935 |
|
NCBI chr 3:70,954,708...71,583,978
Ensembl chr 3:70,954,693...71,583,978
|
|
G |
FOXP3 |
forkhead box P3 |
multiple interactions increases expression |
EXP ISO |
[TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein Sirolimus results in increased expression of FOXP3 mRNA |
CTD |
PMID:20844194 |
|
NCBI chr X:49,250,438...49,264,710
Ensembl chr X:49,250,438...49,264,800
|
|
G |
FRAT1 |
FRAT regulator of WNT signaling pathway 1 |
increases expression |
EXP |
Sirolimus results in increased expression of FRAT1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:97,319,271...97,321,915
Ensembl chr10:97,319,271...97,321,915
|
|
G |
FSHB |
follicle stimulating hormone subunit beta |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [FSHB protein results in increased expression of CCND2 mRNA] |
CTD |
PMID:17510244 |
|
NCBI chr11:30,231,014...30,235,194
Ensembl chr11:30,231,014...30,235,261
|
|
G |
FTL |
ferritin light chain |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr19:48,965,309...48,966,879
Ensembl chr19:48,965,309...48,967,896
|
|
G |
FXN |
frataxin |
multiple interactions |
EXP |
Sirolimus affects the reaction [FXN protein affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol]] |
CTD |
PMID:33017621 |
|
NCBI chr 9:69,035,752...69,079,076
Ensembl chr 9:69,035,751...69,079,076
|
|
G |
GABARAP |
GABA type A receptor-associated protein |
increases expression |
ISO |
Sirolimus results in increased expression of GABARAP mRNA |
CTD |
PMID:21681844 |
|
NCBI chr17:7,240,008...7,242,449
Ensembl chr17:7,240,008...7,242,449
|
|
G |
GABARAPL1 |
GABA type A receptor associated protein like 1 |
multiple interactions |
ISO |
Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein |
CTD |
PMID:15888080 |
|
NCBI chr12:10,212,877...10,223,128
Ensembl chr12:10,212,458...10,223,128
|
|
G |
GCM2 |
glial cells missing transcription factor 2 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein] |
CTD |
PMID:21245298 |
|
NCBI chr 6:10,873,223...10,882,041
Ensembl chr 6:10,873,223...10,882,041
|
|
G |
GEM |
GTP binding protein overexpressed in skeletal muscle |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of GEM mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 8:94,249,253...94,262,319
Ensembl chr 8:94,249,253...94,262,350
|
|
G |
GGT1 |
gamma-glutamyltransferase 1 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Cyclosporine affects the expression of GGT1 protein] |
CTD |
PMID:11589784 |
|
NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005
|
|
G |
GJA1 |
gap junction protein alpha 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of GJA1 protein |
CTD |
PMID:35750204 |
|
NCBI chr 6:121,435,646...121,449,727
Ensembl chr 6:121,435,595...121,449,727
|
|
G |
GLB1 |
galactosidase beta 1 |
multiple interactions decreases expression |
ISO |
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]; Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] Sirolimus results in decreased expression of GLB1 protein |
CTD |
PMID:22561310 |
|
NCBI chr 3:32,961,108...33,097,146
Ensembl chr 3:32,996,609...33,097,202
|
|
G |
GNAI1 |
G protein subunit alpha i1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI1 protein]] |
CTD |
PMID:29748632 |
|
NCBI chr 7:80,134,831...80,226,181
Ensembl chr 7:79,768,028...80,226,181
|
|
G |
GNAI3 |
G protein subunit alpha i3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAI3 protein]] |
CTD |
PMID:29748632 |
|
NCBI chr 1:109,548,615...109,600,195
Ensembl chr 1:109,548,615...109,600,195
|
|
G |
GNAZ |
G protein subunit alpha z |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Dronabinol promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased activity of GNAZ protein]] |
CTD |
PMID:29748632 |
|
NCBI chr22:23,070,519...23,125,032
Ensembl chr22:23,070,519...23,125,032
|
|
G |
GPER1 |
G protein-coupled estrogen receptor 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [puerarin results in increased expression of GPER1 protein] |
CTD |
PMID:27796870 |
|
NCBI chr 7:1,087,118...1,093,810
Ensembl chr 7:1,082,208...1,093,815
|
|
G |
GPNMB |
glycoprotein nmb |
increases expression |
ISO |
Sirolimus results in increased expression of GPNMB mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 7:23,246,775...23,275,108
Ensembl chr 7:23,235,967...23,275,108
|
|
G |
GPR18 |
G protein-coupled receptor 18 |
increases expression |
EXP |
Sirolimus results in increased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:99,254,739...99,258,379
Ensembl chr13:99,254,732...99,261,744
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Cyclosporine affects the expression of GPT protein] Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased activity of GPT protein]] |
CTD |
PMID:11589784 PMID:31499194 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GSDMD |
gasdermin D |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of GSDMD protein] |
CTD |
PMID:37654027 |
|
NCBI chr 8:143,553,387...143,563,062
Ensembl chr 8:143,553,207...143,563,062
|
|
G |
GSK3B |
glycogen synthase kinase 3 beta |
multiple interactions increases activity |
EXP ISO |
[3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Lithium Chloride results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [SB 216763 results in decreased activity of GSK3B protein] inhibits the reaction [Sirolimus results in decreased expression of CCND1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in increased activity of GSK3B protein] which results in increased phosphorylation of and results in increased degradation of CCND1 protein Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:15753396 PMID:17908691 PMID:18495876 |
|
NCBI chr 3:119,821,321...120,094,447
Ensembl chr 3:119,821,321...120,094,994
|
|
G |
GSTT1 |
glutathione S-transferase theta 1 |
increases response to substance |
EXP |
GSTT1 gene mutant form results in increased susceptibility to Sirolimus |
CTD |
PMID:12916871 |
|
|
|
G |
GTPBP4 |
GTP binding protein 4 |
decreases expression |
ISO |
Sirolimus results in decreased expression of GTPBP4 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr10:988,434...1,019,932
Ensembl chr10:988,434...1,019,932
|
|
G |
GUCA2A |
guanylate cyclase activator 2A |
increases expression |
ISO |
Sirolimus results in increased expression of GUCA2A mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:42,162,690...42,164,745
Ensembl chr 1:42,162,690...42,164,745
|
|
G |
GZMB |
granzyme B |
decreases expression |
EXP |
Sirolimus results in decreased expression of GZMB protein |
CTD |
PMID:16477233 |
|
NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267
|
|
G |
H2AX |
H2A.X variant histone |
decreases expression |
EXP |
Sirolimus results in decreased expression of H2AX protein |
CTD |
PMID:23363784 |
|
NCBI chr11:119,093,874...119,095,465
Ensembl chr11:119,093,874...119,095,465
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
Sirolimus results in increased expression of HAVCR1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
|
|
G |
HBP1 |
HMG-box transcription factor 1 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of HBP1 mRNA; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA] |
CTD |
PMID:25307878 PMID:27542212 |
|
NCBI chr 7:107,169,003...107,202,522
Ensembl chr 7:107,168,961...107,202,522
|
|
G |
HES1 |
hes family bHLH transcription factor 1 |
decreases expression |
EXP ISO |
Sirolimus results in decreased expression of HES1 protein Sirolimus results in decreased expression of HES1 mRNA; Sirolimus results in decreased expression of HES1 protein |
CTD |
PMID:20038814 |
|
NCBI chr 3:194,136,148...194,138,732
Ensembl chr 3:194,136,148...194,138,732
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
EXP ISO |
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Oxygen deficiency inhibits the reaction [Sirolimus inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A mRNA]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [sulprostone results in increased expression of HIF1A protein] Sirolimus results in decreased expression of HIF1A protein Sirolimus results in decreased expression of HIF1A mRNA Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein] |
CTD |
PMID:15050414 PMID:15297429 PMID:15634505 PMID:16682453 PMID:17968710 PMID:19335982 PMID:19640849 PMID:20335389 PMID:20554536 PMID:21984483 PMID:27286880 PMID:28574600 PMID:36115647 PMID:36709824 More...
|
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HK2 |
hexokinase 2 |
multiple interactions decreases expression |
EXP |
Curcumin promotes the reaction [Sirolimus results in decreased expression of HK2 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of HK2 protein] |
CTD |
PMID:36336208 PMID:36640941 |
|
NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359
|
|
G |
HMGCR |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
EXP |
Sirolimus results in increased expression of HMGCR mRNA |
CTD |
PMID:17516993 |
|
NCBI chr 5:75,336,529...75,362,116
Ensembl chr 5:75,336,329...75,364,001
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of HMOX1 Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein] |
CTD |
PMID:17003813 PMID:19420259 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNRNPD |
heterogeneous nuclear ribonucleoprotein D |
decreases expression increases expression |
EXP ISO |
Sirolimus results in decreased expression of HNRNPD protein Sirolimus results in increased expression of HNRNPD protein |
CTD |
PMID:17603996 |
|
NCBI chr 4:82,352,498...82,373,991
Ensembl chr 4:82,352,498...82,374,503
|
|
G |
HOXA9 |
homeobox A9 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein] |
CTD |
PMID:21245298 |
|
NCBI chr 7:27,162,438...27,165,537
Ensembl chr 7:27,162,438...27,175,180
|
|
G |
HRAS |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO EXP |
[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein; [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR193A-1 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:24898257 PMID:30619488 |
|
NCBI chr11:532,242...535,576
Ensembl chr11:532,242...537,321
|
|
G |
HSF1 |
heat shock transcription factor 1 |
increases activity |
EXP |
Sirolimus results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 8:144,291,604...144,314,720
Ensembl chr 8:144,291,591...144,314,720
|
|
G |
HSPA1B |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
EXP |
Sirolimus results in decreased expression of HSPA1B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression multiple interactions |
EXP ISO |
Sirolimus results in decreased expression of HSPA5 mRNA [Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] Sirolimus inhibits the reaction [cadmium acetate results in increased expression of HSPA5 protein] |
CTD |
PMID:24356939 PMID:24898257 PMID:29870746 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HSPB8 |
heat shock protein family B (small) member 8 |
decreases expression |
EXP |
Sirolimus results in decreased expression of HSPB8 protein |
CTD |
PMID:21233418 |
|
NCBI chr12:119,178,931...119,194,746
Ensembl chr12:119,171,555...119,224,855
|
|
G |
IBSP |
integrin binding sialoprotein |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] |
CTD |
PMID:31051157 |
|
NCBI chr 4:87,799,554...87,812,435
Ensembl chr 4:87,799,554...87,812,435
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of ICAM1 protein |
CTD |
PMID:12531798 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
ID1 |
inhibitor of DNA binding 1 |
increases expression |
EXP |
Sirolimus results in increased expression of ID1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr20:31,605,289...31,606,510
Ensembl chr20:31,573,014...31,606,515
|
|
G |
IFNG |
interferon gamma |
multiple interactions decreases secretion |
EXP ISO |
Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein] Sirolimus results in decreased secretion of IFNG protein Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] |
CTD |
PMID:11692113 PMID:16427044 PMID:21600178 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGF1 |
insulin like growth factor 1 |
multiple interactions increases response to substance |
EXP ISO |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IGF1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of ACTA2 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of CALD1 protein; [Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein] Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA] Sirolimus results in increased susceptibility to IGF1 protein Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1A protein]; Sirolimus inhibits the reaction [IGF1 protein affects the localization of CDKN1B protein]; Sirolimus inhibits the reaction [IGF1 protein inhibits the reaction [Isoflurane results in decreased phosphorylation of AKT1 protein]]; Sirolimus inhibits the reaction [IGF1 protein results in increased expression of CCND1 protein] |
CTD |
PMID:11355896 PMID:15070696 PMID:15297429 PMID:16227402 PMID:16682453 PMID:17908691 PMID:19105244 PMID:25597859 More...
|
|
NCBI chr12:102,395,874...102,481,839
Ensembl chr12:102,395,874...102,481,744
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
affects activity multiple interactions |
EXP |
Sirolimus affects the activity of IGF1R protein Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:16227402 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
increases expression |
ISO |
Sirolimus results in increased expression of IGFBP1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
IGFBP3 |
insulin like growth factor binding protein 3 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of IGFBP3 protein] |
CTD |
PMID:16682453 |
|
NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
|
|
G |
IGFBP5 |
insulin like growth factor binding protein 5 |
decreases expression |
ISO |
Sirolimus results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549
|
|
G |
IL10 |
interleukin 10 |
multiple interactions decreases expression |
EXP ISO |
Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [lipoteichoic acid results in increased expression of IL10 protein]; Sirolimus inhibits the reaction [Peptidoglycan results in increased expression of IL10 protein] [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL10 protein; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]] Sirolimus results in decreased expression of IL10 protein Sirolimus results in decreased expression of IL10 mRNA |
CTD |
PMID:11169223 PMID:15588918 PMID:31499194 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12A |
interleukin 12A |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:12531798 |
|
NCBI chr 3:159,988,835...159,996,019
Ensembl chr 3:159,988,835...159,996,019
|
|
G |
IL12B |
interleukin 12B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:12531798 |
|
NCBI chr 5:159,314,780...159,330,487
Ensembl chr 5:159,314,780...159,330,863
|
|
G |
IL17A |
interleukin 17A |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of IL17A protein] |
CTD |
PMID:36849104 |
|
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
G |
IL17RB |
interleukin 17 receptor B |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of IL17RB mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 3:53,846,568...53,865,794
Ensembl chr 3:53,846,568...53,865,794
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] Sirolimus inhibits the reaction [Particulate Matter results in increased expression of IL18 protein] |
CTD |
PMID:30205151 PMID:38237716 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,251...112,164,096
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions affects expression increases expression |
ISO EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased cleavage of IL1B protein]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of IL1B mRNA] Sirolimus affects the expression of IL1B mRNA Sirolimus results in increased expression of IL1B protein Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of IL1B protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]] Sirolimus results in increased expression of IL1B mRNA Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein] |
CTD |
PMID:22363816 PMID:23211629 PMID:24971338 PMID:25045214 PMID:29594315 PMID:30205151 PMID:31499194 PMID:31586597 PMID:33823232 PMID:35405287 PMID:36799065 PMID:36849104 PMID:38237716 More...
|
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
multiple interactions decreases response to substance affects expression |
EXP ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND2 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased expression of CCND3 protein]; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CCND3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein] Sirolimus results in decreased susceptibility to IL2 protein [Sirolimus co-treated with IL2 protein] results in decreased expression of BCL2A1A mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2 mRNA; [Sirolimus co-treated with IL2 protein] results in increased expression of BCL2L1 mRNA; [Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein; Sirolimus inhibits the reaction [IL2 protein results in decreased expression of CCNI mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of ASNS mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BAD mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BNIP3 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of BTK mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of CDK1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of IGF1 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]] Sirolimus affects the expression of IL2 protein Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]] |
CTD |
PMID:1614535 PMID:10373522 PMID:11355896 PMID:15588918 PMID:15778701 PMID:24971338 PMID:25045214 PMID:29594315 More...
|
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
IL2RA |
interleukin 2 receptor subunit alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein]; Sirolimus inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2RA protein] |
CTD |
PMID:8586487 |
|
NCBI chr10:6,010,689...6,062,367
Ensembl chr10:6,010,689...6,062,370
|
|
G |
IL2RG |
interleukin 2 receptor subunit gamma |
multiple interactions |
ISO |
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL2RG protein |
CTD |
PMID:12531798 |
|
NCBI chr X:71,107,404...71,111,577
Ensembl chr X:71,107,404...71,112,108
|
|
G |
IL3 |
interleukin 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL3 protein]] |
CTD |
PMID:1376361 |
|
NCBI chr 5:132,060,655...132,063,204
Ensembl chr 5:132,060,655...132,063,204
|
|
G |
IL4 |
interleukin 4 |
multiple interactions decreases expression |
ISO |
[Sirolimus co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL4 protein; Sirolimus inhibits the reaction [IL4 protein results in increased expression of [IL12A protein binds to IL12B protein]] Sirolimus analog results in decreased expression of IL4 protein; Sirolimus results in decreased expression of IL4 protein |
CTD |
PMID:12406821 PMID:12531798 PMID:15588918 |
|
NCBI chr 5:132,673,989...132,682,678
Ensembl chr 5:132,673,986...132,682,678
|
|
G |
IL4R |
interleukin 4 receptor |
multiple interactions |
ISO |
[Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R mRNA; [Sirolimus binds to FKBP1A protein] which results in decreased expression of IL4R protein |
CTD |
PMID:12531798 |
|
NCBI chr16:27,313,756...27,364,778
Ensembl chr16:27,313,668...27,364,778
|
|
G |
IL5 |
interleukin 5 |
decreases expression |
ISO |
Sirolimus analog results in decreased expression of IL5 protein |
CTD |
PMID:12406821 |
|
NCBI chr 5:132,541,445...132,556,815
Ensembl chr 5:132,541,445...132,556,838
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression increases expression |
EXP ISO |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] results in decreased activity of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein Sirolimus results in decreased expression of IL6 mRNA Sirolimus results in increased expression of IL6 Sirolimus inhibits the reaction [[Rotenone co-treated with Particulate Matter] results in increased expression of IL6 mRNA] |
CTD |
PMID:15070696 PMID:16314788 PMID:20844194 PMID:33823232 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
ING4 |
inhibitor of growth family member 4 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr12:6,650,301...6,663,119
Ensembl chr12:6,650,301...6,663,142
|
|
G |
INS |
insulin |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:20936651 PMID:28790194 PMID:28984034 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INS-IGF2 |
INS-IGF2 readthrough |
decreases expression multiple interactions |
ISO EXP |
Sirolimus results in decreased expression of INS1 protein Sirolimus inhibits the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] Sirolimus inhibits the reaction [Carbachol results in increased secretion of INS1 protein]; Sirolimus inhibits the reaction [Glucose results in increased secretion of INS1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14578291 PMID:20880397 PMID:21357504 PMID:23920219 PMID:26563389 PMID:32283200 More...
|
|
NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209
|
|
G |
INSIG1 |
insulin induced gene 1 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of INSIG1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235
|
|
G |
IRS1 |
insulin receptor substrate 1 |
affects phosphorylation multiple interactions decreases degradation decreases phosphorylation |
EXP |
Sirolimus affects the phosphorylation of IRS1 protein [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased phosphorylation of IRS1 protein]]; Sirolimus inhibits the reaction [INS protein results in increased expression of IRS1 protein modified form]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IGF1R protein binds to and results in increased phosphorylation of IRS1 protein]; Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] Sirolimus results in decreased degradation of IRS1 protein Sirolimus results in decreased phosphorylation of IRS1 protein |
CTD |
PMID:16227402 PMID:17908691 PMID:20936651 PMID:28984034 |
|
NCBI chr 2:226,731,312...226,799,820
Ensembl chr 2:226,731,312...226,799,820
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions increases expression |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein]; [Sirolimus co-treated with arsenic trioxide] results in increased expression of ITGAM protein; Sirolimus promotes the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein] Sirolimus results in increased expression of ITGAM protein |
CTD |
PMID:20574048 PMID:25758096 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
ITGAV |
integrin subunit alpha V |
decreases expression |
ISO |
Sirolimus results in decreased expression of ITGAV mRNA; Sirolimus results in decreased expression of ITGAV protein |
CTD |
PMID:19922502 |
|
NCBI chr 2:186,590,056...186,680,901
Ensembl chr 2:186,590,010...186,680,901
|
|
G |
JAG1 |
jagged canonical Notch ligand 1 |
decreases expression |
EXP ISO |
Sirolimus results in decreased expression of JAG1 protein |
CTD |
PMID:20038814 |
|
NCBI chr20:10,637,684...10,673,999
Ensembl chr20:10,637,684...10,673,999
|
|
G |
JMY |
junction mediating and regulatory protein, p53 cofactor |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:79,236,131...79,327,211
Ensembl chr 5:79,236,131...79,327,211
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of JUN protein] |
CTD |
PMID:26369790 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KEAP1 |
kelch like ECH associated protein 1 |
increases expression multiple interactions |
EXP |
Sirolimus results in increased expression of KEAP1 protein Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [Particulate Matter affects the expression of KEAP1 protein]] |
CTD |
PMID:29781141 |
|
NCBI chr19:10,486,125...10,503,356
Ensembl chr19:10,486,125...10,503,558
|
|
G |
KIFAP3 |
kinesin associated protein 3 |
increases expression |
ISO |
Sirolimus results in increased expression of KIFAP3 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:169,921,329...170,085,184
Ensembl chr 1:169,921,326...170,085,208
|
|
G |
KIFC1 |
kinesin family member C1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of KIFC1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 6:33,391,461...33,409,896
Ensembl chr 6:33,391,823...33,409,896
|
|
G |
KIT |
KIT proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP |
KIT protein mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:16597595 |
|
NCBI chr 4:54,657,957...54,740,715
Ensembl chr 4:54,657,267...54,740,783
|
|
G |
KITLG |
KIT ligand |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [KITL protein results in increased expression of CCND3 protein]; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] |
CTD |
PMID:10849422 |
|
NCBI chr12:88,492,793...88,580,471
Ensembl chr12:88,492,793...88,580,851
|
|
G |
KLF2 |
KLF transcription factor 2 |
increases expression |
EXP |
Sirolimus results in increased expression of KLF2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685
|
|
G |
KLF5 |
KLF transcription factor 5 |
increases expression |
ISO |
Sirolimus results in increased expression of KLF5 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
|
|
G |
KLF6 |
KLF transcription factor 6 |
decreases phosphorylation |
ISO |
Sirolimus results in decreased phosphorylation of KLF6 protein |
CTD |
PMID:16611854 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KLHL24 |
kelch like family member 24 |
increases expression multiple interactions |
EXP |
Sirolimus results in increased expression of KLHL24 mRNA [(+)-JQ1 compound co-treated with Sirolimus] affects the expression of KLHL24 mRNA |
CTD |
PMID:24356939 PMID:25307878 |
|
NCBI chr 3:183,635,623...183,684,519
Ensembl chr 3:183,635,610...183,684,519
|
|
G |
KLK2 |
kallikrein related peptidase 2 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [Testosterone results in increased expression of KLK2 protein] |
CTD |
PMID:21036700 |
|
NCBI chr19:50,873,439...50,880,567
Ensembl chr19:50,861,568...50,880,567
|
|
G |
KLK3 |
kallikrein related peptidase 3 |
multiple interactions increases expression decreases expression |
EXP ISO |
bicalutamide inhibits the reaction [Sirolimus results in increased expression of KLK3 protein] Sirolimus results in decreased expression of KLK1C10 mRNA |
CTD |
PMID:18776922 PMID:21865292 |
|
NCBI chr19:50,854,915...50,860,764
Ensembl chr19:50,854,915...50,860,764
|
|
G |
L1CAM |
L1 cell adhesion molecule |
affects response to substance |
EXP |
L1CAM affects the susceptibility to Sirolimus |
CTD |
PMID:21097529 |
|
NCBI chr X:153,861,514...153,886,173
Ensembl chr X:153,861,514...153,886,173
|
|
G |
LAMC2 |
laminin subunit gamma 2 |
increases expression |
ISO |
Sirolimus results in increased expression of LAMC2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:183,186,264...183,258,968
Ensembl chr 1:183,186,238...183,245,127
|
|
G |
LARP1 |
La ribonucleoprotein 1, translational regulator |
multiple interactions increases response to substance |
EXP |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA] LARP1 protein results in increased susceptibility to Sirolimus |
CTD |
PMID:25940091 |
|
NCBI chr 5:154,682,979...154,817,605
Ensembl chr 5:154,682,986...154,817,605
|
|
G |
LAT2 |
linker for activation of T cells family member 2 |
increases response to substance |
EXP |
LAT2 protein results in increased susceptibility to Sirolimus |
CTD |
PMID:32587277 |
|
NCBI chr 7:74,210,006...74,229,834
Ensembl chr 7:74,199,652...74,229,834
|
|
G |
LCN2 |
lipocalin 2 |
increases expression |
ISO |
Sirolimus results in increased expression of LCN2 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
LDHA |
lactate dehydrogenase A |
multiple interactions increases expression |
EXP |
Curcumin inhibits the reaction [Sirolimus results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LDHA protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of LDHA protein] |
CTD |
PMID:36336208 PMID:36640941 |
|
NCBI chr11:18,394,563...18,408,425
Ensembl chr11:18,394,560...18,408,425
|
|
G |
LIF |
LIF interleukin 6 family cytokine |
multiple interactions |
ISO |
Sirolimus promotes the reaction [cypermethrin results in decreased expression of LIF protein] |
CTD |
PMID:37011868 |
|
NCBI chr22:30,240,453...30,246,759
Ensembl chr22:30,240,453...30,246,759
|
|
G |
LIPE |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Isoproterenol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:21042876 |
|
NCBI chr19:42,401,514...42,427,388
Ensembl chr19:42,401,497...42,427,388
|
|
G |
LMNB1 |
lamin B1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of and affects the localization of LMNB1 protein] |
CTD |
PMID:38604309 |
|
NCBI chr 5:126,776,623...126,837,020
Ensembl chr 5:126,776,623...126,837,020
|
|
G |
MAD2L1 |
mitotic arrest deficient 2 like 1 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 4:120,055,623...120,066,848
Ensembl chr 4:120,055,623...120,066,858
|
|
G |
MAF1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
EXP |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Sirolimus] results in decreased degradation of MAF1 protein; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; Sirolimus results in increased expression of and results in decreased phosphorylation of MAF1 protein |
CTD |
PMID:31645432 |
|
NCBI chr 8:144,104,461...144,107,611
Ensembl chr 8:144,104,420...144,107,611
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
multiple interactions |
EXP |
[Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form |
CTD |
PMID:21742779 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression affects localization multiple interactions affects metabolic processing increases lipidation |
EXP ISO |
Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein; Sirolimus results in increased expression of MAP1LC3B protein modified form Sirolimus affects the localization of MAP1LC3B protein 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; saikosaponin D inhibits the reaction [Sirolimus results in increased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [Particulate Matter results in increased lipidation of and results in increased localization of MAP1LC3B protein]; Sirolimus inhibits the reaction [saikosaponin D results in decreased cleavage of MAP1LC3B protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Lipopolysaccharides results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; Sirolimus results in increased expression of and results in increased cleavage of MAP1LC3B protein Sirolimus results in increased expression of MAP1LC3B mRNA; Sirolimus results in increased expression of MAP1LC3B protein modified form Sirolimus affects the metabolism of MAP1LC3B protein CD38 gene mutant form promotes the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]]; Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Ethanol results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Tunicamycin results in increased lipidation of MAP1LC3B protein] [bisphenol A co-treated with Sirolimus] results in increased lipidation of MAP1LC3B protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein]; PRKD2 protein affects the reaction [Sirolimus results in increased lipidation of MAP1LC3B protein]; Sirolimus inhibits the reaction [honokiol results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; Sirolimus promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [hydroquinone results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; Sirolimus promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:18640276 PMID:19815708 PMID:21212465 PMID:21681844 PMID:23680031 PMID:24445604 PMID:25884947 PMID:27107786 PMID:29128638 PMID:29518472 PMID:29793971 PMID:30338810 PMID:30555576 PMID:30611790 PMID:31676321 PMID:33002460 PMID:33550458 PMID:34281243 PMID:34634291 PMID:35134463 PMID:35405287 PMID:35472370 PMID:35872226 PMID:36640941 PMID:36708882 PMID:37148176 PMID:37654027 PMID:37951334 PMID:38237716 More...
|
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP2 |
microtubule associated protein 2 |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of MAP2 protein 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein]; Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 2:209,424,047...209,734,112
Ensembl chr 2:209,424,047...209,734,147
|
|
G |
MAP2K1 |
mitogen-activated protein kinase kinase 1 |
multiple interactions |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein; [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:12411397 PMID:15767555 |
|
NCBI chr15:66,386,912...66,491,544
Ensembl chr15:66,386,837...66,491,656
|
|
G |
MAP2K2 |
mitogen-activated protein kinase kinase 2 |
multiple interactions |
EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K2 protein |
CTD |
PMID:15767555 |
|
NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation affects phosphorylation |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; arsenic trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK1 protein modified form] Sirolimus results in decreased phosphorylation of MAPK1 protein [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK1 protein] Sirolimus inhibits the reaction [[IGF1 protein co-treated with U 0126] promotes the reaction [Isoflurane results in decreased phosphorylation of MAPK1 protein]] Sirolimus affects the phosphorylation of MAPK1 protein |
CTD |
PMID:15767555 PMID:16255777 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25597859 PMID:25758096 PMID:30905858 More...
|
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation affects phosphorylation |
EXP ISO |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Arsenic Trioxide inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Sirolimus inhibits the reaction [INS protein results in increased expression of MAPK3 protein modified form] Sirolimus results in decreased phosphorylation of MAPK3 protein [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of MAPK3 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Sirolimus results in increased phosphorylation of MAPK3 protein] Sirolimus affects the phosphorylation of MAPK3 protein |
CTD |
PMID:15767555 PMID:16255777 PMID:16391472 PMID:18374093 PMID:19151764 PMID:20936651 PMID:21984483 PMID:22363816 PMID:24392034 PMID:25758096 PMID:30905858 More...
|
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in increased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15767555 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPT |
microtubule associated protein tau |
multiple interactions |
EXP |
Sirolimus results in decreased expression of and results in decreased cleavage of MAPT protein |
CTD |
PMID:33124469 |
|
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
|
|
G |
MBNL2 |
muscleblind like splicing regulator 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr13:97,141,834...97,394,120
Ensembl chr13:97,221,434...97,394,120
|
|
G |
MBP |
myelin basic protein |
increases expression |
ISO |
Sirolimus results in increased expression of MBP protein |
CTD |
PMID:20739560 |
|
NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MCL1 protein; [Sirolimus co-treated with Arsenic Trioxide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of MCL1 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of CASP3 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased stability of and results in decreased ubiquitination of MCL1 protein] |
CTD |
PMID:15767555 PMID:25758096 PMID:32802178 |
|
NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738
|
|
G |
MCM2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM2 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 3:127,598,411...127,622,436
Ensembl chr 3:127,598,223...127,622,436
|
|
G |
MCM7 |
minichromosome maintenance complex component 7 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [IL2 protein results in increased expression of MCM7 mRNA] |
CTD |
PMID:11355896 |
|
NCBI chr 7:100,092,728...100,101,397
Ensembl chr 7:100,092,233...100,101,940
|
|
G |
MDM2 |
MDM2 proto-oncogene |
multiple interactions decreases expression |
EXP |
EIF4E protein inhibits the reaction [Sirolimus results in decreased expression of MDM2 protein]; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter] |
CTD |
PMID:15625077 PMID:19560264 PMID:21245298 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MIR122 |
microRNA 122 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR122 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr18:58,451,074...58,451,158
Ensembl chr18:58,451,074...58,451,158
|
|
G |
MIR132 |
microRNA 132 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR132 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr17:2,049,908...2,050,008
Ensembl chr17:2,049,908...2,050,008
|
|
G |
MIR146A |
microRNA 146a |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [HRAS protein mutant form results in increased expression of MIR146A mRNA] |
CTD |
PMID:30619488 |
|
NCBI chr 5:160,485,352...160,485,450
Ensembl chr 5:160,485,352...160,485,450
|
|
G |
MIR151A |
microRNA 151a |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 8:140,732,564...140,732,653
Ensembl chr 8:140,732,564...140,732,653
|
|
G |
MIR181A2 |
microRNA 181a-2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 9:124,692,442...124,692,551
Ensembl chr 9:124,692,442...124,692,551
|
|
G |
MIR190A |
microRNA 190a |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr15:62,823,957...62,824,041
Ensembl chr15:62,823,957...62,824,041
|
|
G |
MIR212 |
microRNA 212 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [INS1 protein results in increased expression of MIR212 mRNA] |
CTD |
PMID:23920219 |
|
NCBI chr17:2,050,271...2,050,380
Ensembl chr17:2,050,271...2,050,380
|
|
G |
MIR29C |
microRNA 29c |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 1:207,801,852...207,801,939
Ensembl chr 1:207,801,852...207,801,939
|
|
G |
MIR324 |
microRNA 324 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr17:7,223,297...7,223,379
Ensembl chr17:7,223,297...7,223,379
|
|
G |
MIR330 |
microRNA 330 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MIR330 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr19:45,638,994...45,639,087
Ensembl chr19:45,638,994...45,639,087
|
|
G |
MIR379 |
microRNA 379 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:101,022,066...101,022,132
Ensembl chr14:101,022,066...101,022,132
|
|
G |
MIR433 |
microRNA 433 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:100,881,886...100,881,978
Ensembl chr14:100,881,886...100,881,978
|
|
G |
MIR503 |
microRNA 503 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr X:134,546,328...134,546,398
Ensembl chr X:134,546,328...134,546,398
|
|
G |
MIR508 |
microRNA 508 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr X:147,236,913...147,237,027
Ensembl chr X:147,236,913...147,237,027
|
|
G |
MIR650 |
microRNA 650 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr22:22,822,776...22,822,871
Ensembl chr22:22,822,776...22,822,871
|
|
G |
MIR654 |
microRNA 654 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:101,040,219...101,040,299
Ensembl chr14:101,040,219...101,040,299
|
|
G |
MIR758 |
microRNA 758 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:101,026,020...101,026,107
Ensembl chr14:101,026,020...101,026,107
|
|
G |
MIR760 |
microRNA 760 |
multiple interactions |
EXP |
TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 1:93,846,832...93,846,911
Ensembl chr 1:93,846,832...93,846,911
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions affects expression |
EXP ISO |
Sirolimus results in decreased expression of MKI67 protein [ABT-737 co-treated with Sirolimus] results in decreased expression of MKI67 protein Sirolimus affects the expression of MKI67 mRNA |
CTD |
PMID:19773376 PMID:24971338 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MLST8 |
MTOR associated protein, LST8 homolog |
multiple interactions |
EXP |
Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein] |
CTD |
PMID:19505958 |
|
NCBI chr16:2,205,454...2,209,453
Ensembl chr16:2,204,248...2,209,453
|
|
G |
MMP1 |
matrix metallopeptidase 1 |
increases secretion increases expression |
EXP |
Sirolimus results in increased secretion of MMP1 protein Sirolimus results in increased expression of MMP1 mRNA |
CTD |
PMID:21742783 |
|
NCBI chr11:102,789,919...102,798,160
Ensembl chr11:102,789,401...102,798,160
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO EXP |
Sirolimus inhibits the reaction [Thioacetamide results in increased activity of MMP2 protein] Curcumin inhibits the reaction [Sirolimus results in increased expression of MMP2 protein]; Sirolimus inhibits the reaction [Chloroquine results in decreased expression of MMP2 protein]; Sirolimus inhibits the reaction [Hydroxychloroquine results in decreased expression of MMP2 protein] |
CTD |
PMID:17050028 PMID:34278709 PMID:36640941 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions increases expression |
ISO EXP |
Sirolimus results in decreased expression of MMP9 mRNA Sirolimus promotes the reaction [cypermethrin results in decreased expression of MMP9 protein] Sirolimus results in increased expression of MMP9 protein Curcumin inhibits the reaction [Sirolimus results in increased expression of MMP9 protein] |
CTD |
PMID:21865292 PMID:36640941 PMID:37011868 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MPZ |
myelin protein zero |
increases expression |
ISO |
Sirolimus results in increased expression of MPZ protein |
CTD |
PMID:20739560 |
|
NCBI chr 1:161,303,600...161,309,968
Ensembl chr 1:161,304,735...161,309,968
|
|
G |
MSR1 |
macrophage scavenger receptor 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of MSR1 mRNA |
CTD |
PMID:17016853 |
|
NCBI chr 8:16,107,881...16,192,651
Ensembl chr 8:16,107,878...16,567,490
|
|
G |
MT1E |
metallothionein 1E |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1E mRNA |
CTD |
PMID:25307878 |
|
NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112
|
|
G |
MT1G |
metallothionein 1G |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1G mRNA |
CTD |
PMID:25307878 |
|
NCBI chr16:56,666,730...56,668,065
Ensembl chr16:56,666,730...56,668,065
|
|
G |
MT1H |
metallothionein 1H |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1H mRNA |
CTD |
PMID:25307878 |
|
NCBI chr16:56,669,814...56,671,129
Ensembl chr16:56,669,814...56,671,129
|
|
G |
MT1M |
metallothionein 1M |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of MT1M mRNA |
CTD |
PMID:25307878 |
|
NCBI chr16:56,632,659...56,633,981
Ensembl chr16:56,632,659...56,633,981
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions decreases activity decreases expression increases activity decreases phosphorylation increases phosphorylation increases expression affects binding |
EXP ISO |
[Oxygen deficiency co-treated with Sirolimus] results in decreased expression of MTOR protein; [Sirolimus co-treated with Photosensitizing Agents] affects the phosphorylation of MTOR protein; [Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of DDIT3 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of EIF4EBP1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased phosphorylation of GSK3B protein; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to afimoxifene; [Sirolimus results in decreased activity of MTOR protein] which results in increased susceptibility to Fulvestrant; [Sirolimus results in decreased phosphorylation of MTOR protein] which results in decreased chemical synthesis of Reactive Oxygen Species; Curcumin promotes the reaction [Sirolimus results in decreased phosphorylation of MTOR protein]; MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sevoflurane promotes the reaction [Sirolimus results in decreased phosphorylation of MTOR protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of MTOR mRNA]; Sirolimus inhibits the reaction [Palmitic Acid results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Serotonin results in increased activity of MTOR protein]; Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in decreased expression of and results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [Cisplatin results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [hydroquinone results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [Sevoflurane results in decreased phosphorylation of MTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]; Sirolimus results in decreased expression of and results in decreased phosphorylation of MTOR protein; Sirolimus results in decreased phosphorylation of and results in increased expression of MTOR protein; sodium arsenite promotes the reaction [Sirolimus results in decreased expression of MTOR protein] [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of MTOR protein Sirolimus results in decreased expression of MTOR mRNA; Sirolimus results in decreased expression of MTOR protein; Sirolimus results in decreased expression of MTOR protein modified form Sirolimus results in increased activity of MTOR protein [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol affects the susceptibility to Lipopolysaccharides]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of CREB1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased susceptibility to Resveratrol; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Creatine results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus promotes the reaction [Arsenic Trioxide results in decreased phosphorylation of MTOR protein]; Sirolimus promotes the reaction [cypermethrin results in decreased phosphorylation of MTOR protein] Sirolimus results in increased phosphorylation of MTOR protein Sirolimus results in increased expression of MTOR mRNA [Silicon Dioxide co-treated with Sirolimus] results in decreased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,2',3,5',6-pentachlorobiphenyl results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [Paraquat results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]] Sirolimus results in increased expression of MTOR protein modified form Sirolimus binds to MTOR protein |
CTD |
PMID:11602639 PMID:12087098 PMID:14673156 PMID:15050414 PMID:15782132 PMID:15919668 PMID:17623046 PMID:17908691 PMID:17968710 PMID:17996122 PMID:18058806 PMID:18381446 PMID:18640276 PMID:18776922 PMID:19016759 PMID:19125612 PMID:19151764 PMID:19505958 PMID:19567381 PMID:19698219 PMID:19815708 PMID:19995983 PMID:20169165 PMID:20368307 PMID:20680277 PMID:20682991 PMID:21168265 PMID:21187475 PMID:21321189 PMID:21450334 PMID:21742779 PMID:21898527 PMID:22069489 PMID:22363816 PMID:22561310 PMID:22574221 PMID:23111315 PMID:23363784 PMID:23396362 PMID:23958494 PMID:24971338 PMID:25045214 PMID:25576684 PMID:25884947 PMID:25940091 PMID:26201060 PMID:26282490 PMID:26648565 PMID:27107786 PMID:27133527 PMID:27324791 PMID:27796870 PMID:28342888 PMID:28888487 PMID:29518472 PMID:29650965 PMID:30132043 PMID:30236763 PMID:30555576 PMID:31051157 PMID:31499194 PMID:32044396 PMID:32156566 PMID:32329240 PMID:32802178 PMID:33022268 PMID:33124469 PMID:33462182 PMID:33720480 PMID:33823232 PMID:33838154 PMID:34453960 PMID:34536393 PMID:35134463 PMID:35472370 PMID:35985552 PMID:36115647 PMID:36336208 PMID:36639017 PMID:36640941 PMID:36799065 PMID:36849104 PMID:37011868 PMID:37148176 PMID:37290678 PMID:37329965 PMID:38574842 More...
|
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MTURN |
maturin, neural progenitor differentiation regulator homolog |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:30,134,986...30,162,762
Ensembl chr 7:30,134,986...30,162,765
|
|
G |
MYBL2 |
MYB proto-oncogene like 2 |
multiple interactions |
ISO |
[TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein |
CTD |
PMID:12417722 |
|
NCBI chr20:43,667,114...43,716,482
Ensembl chr20:43,667,019...43,716,495
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of MYC protein; [(+)-JQ1 compound co-treated with Sirolimus] results in increased expression of MYC mRNA; [Sirolimus co-treated with letrozole] results in decreased expression of MYC protein |
CTD |
PMID:20054642 PMID:25307878 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
MYF5 |
myogenic factor 5 |
decreases expression |
ISO |
Sirolimus results in decreased expression of MYF5 protein |
CTD |
PMID:30905858 |
|
NCBI chr12:80,716,912...80,719,671
Ensembl chr12:80,716,912...80,719,671
|
|
G |
MYH11 |
myosin heavy chain 11 |
multiple interactions increases expression |
EXP |
[Sirolimus co-treated with IGF1 protein] results in increased expression of MYH11 protein; [Sirolimus results in increased activity of AKT2 protein] which results in increased expression of MYH11 protein Sirolimus results in increased expression of MYH11 protein |
CTD |
PMID:17908691 |
|
NCBI chr16:15,703,135...15,857,028
Ensembl chr16:15,703,135...15,858,438
|
|
G |
MYH7 |
myosin heavy chain 7 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr14:23,412,740...23,435,660
Ensembl chr14:23,412,740...23,435,660
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 3:123,610,049...123,884,332
Ensembl chr 3:123,610,049...123,884,332
|
|
G |
MYOD1 |
myogenic differentiation 1 |
affects expression |
ISO |
Sirolimus affects the expression of MYOD1 protein |
CTD |
PMID:30905858 |
|
NCBI chr11:17,719,571...17,722,136
Ensembl chr11:17,719,571...17,722,136
|
|
G |
MYOF |
myoferlin |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr10:93,306,429...93,482,334
Ensembl chr10:93,306,429...93,482,334
|
|
G |
NAIP |
NLR family apoptosis inhibitory protein |
decreases expression |
ISO |
Sirolimus results in decreased expression of NAIP mRNA |
CTD |
PMID:9836529 |
|
NCBI chr 5:70,968,166...71,025,339
Ensembl chr 5:70,968,166...71,025,339
|
|
G |
NANOG |
Nanog homeobox |
increases expression |
ISO |
Sirolimus results in increased expression of NANOG mRNA |
CTD |
PMID:21681844 |
|
NCBI chr12:7,789,402...7,799,146
Ensembl chr12:7,787,794...7,799,146
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
multiple interactions decreases expression |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF1 protein] Sirolimus results in decreased expression of NCF1 protein |
CTD |
PMID:21195169 |
|
NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315
|
|
G |
NCF2 |
neutrophil cytosolic factor 2 |
decreases expression multiple interactions |
ISO |
Sirolimus results in decreased expression of NCF2 protein Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF2 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 1:183,555,562...183,601,849
Ensembl chr 1:183,554,461...183,590,905
|
|
G |
NCF4 |
neutrophil cytosolic factor 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of NCF4 protein] |
CTD |
PMID:21195169 |
|
NCBI chr22:36,861,006...36,878,015
Ensembl chr22:36,860,988...36,878,017
|
|
G |
NDC80 |
NDC80 kinetochore complex component |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NDC80 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr18:2,571,557...2,616,635
Ensembl chr18:2,571,557...2,616,635
|
|
G |
NEK2 |
NIMA related kinase 2 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NEK2 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 1:211,658,256...211,675,621
Ensembl chr 1:211,658,657...211,675,630
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity |
ISO |
NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in decreased expression of CDH1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 mRNA]; Sirolimus inhibits the reaction [Paraquat results in decreased expression of NFE2L2 protein] Sirolimus results in increased activity of NFE2L2 protein |
CTD |
PMID:28624451 PMID:30203046 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756
|
|
G |
NFKB1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Doxorubicin results in increased activity of NFKB1 protein] |
CTD |
PMID:15571967 |
|
NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [Doxorubicin results in increased degradation of and results in decreased expression of NFKBIA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Sirolimus inhibits the reaction [Isoproterenol results in increased degradation of NFKBIA protein]; Sirolimus inhibits the reaction [Pilocarpine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:15571967 PMID:18789402 PMID:22363816 PMID:23211629 PMID:25045214 |
|
NCBI chr14:35,401,513...35,404,749
Ensembl chr14:35,401,079...35,404,749
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions decreases expression |
EXP ISO |
Sirolimus inhibits the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein] Sirolimus results in decreased expression of NLRP3 protein Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of NLRP3 protein]; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of NLRP3 protein]; Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of NLRP3 mRNA] Sirolimus inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein] |
CTD |
PMID:30205151 PMID:32645460 PMID:35405287 PMID:36849104 PMID:37654027 PMID:38237716 More...
|
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,332,331...247,449,108
|
|
G |
NME1 |
NME/NM23 nucleoside diphosphate kinase 1 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of NME1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr17:51,153,559...51,162,168
Ensembl chr17:51,153,559...51,162,428
|
|
G |
NMU |
neuromedin U |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 4:55,595,231...55,636,793
Ensembl chr 4:55,595,229...55,636,698
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of NOS2 protein] |
CTD |
PMID:22363816 PMID:23211629 PMID:31499194 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions decreases expression increases phosphorylation |
EXP ISO |
Aspirin inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of NOS3 protein] Sirolimus results in decreased expression of NOS3 mRNA; Sirolimus results in decreased expression of NOS3 protein Sirolimus results in increased phosphorylation of NOS3 protein |
CTD |
PMID:17261647 PMID:19520256 PMID:19815708 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NOTCH1 |
notch receptor 1 |
affects expression |
ISO |
Sirolimus affects the expression of NOTCH1 protein |
CTD |
PMID:26676567 |
|
NCBI chr 9:136,494,433...136,546,048
Ensembl chr 9:136,494,433...136,546,048
|
|
G |
NPHS2 |
NPHS2 stomatin family member, podocin |
affects expression |
ISO |
Sirolimus affects the expression of NPHS2 protein |
CTD |
PMID:19671594 |
|
NCBI chr 1:179,550,539...179,575,948
Ensembl chr 1:179,550,539...179,575,952
|
|
G |
NPPA |
natriuretic peptide A |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]; Sirolimus inhibits the reaction [rosiglitazone results in increased expression of NPPA mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]] |
CTD |
PMID:19397913 PMID:25045214 |
|
NCBI chr 1:11,845,709...11,847,783
Ensembl chr 1:11,845,709...11,848,345
|
|
G |
NPPB |
natriuretic peptide B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]] |
CTD |
PMID:25045214 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
affects expression increases expression |
EXP |
Sirolimus affects the expression of NR1H3 protein Sirolimus increases expression of NR1H3 mRNA in macrophages |
CTD RGD |
PMID:17016853 PMID:17016853 |
RGD:401827916 |
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
increases activity |
ISO |
Sirolimus results in increased activity of NR3C1 protein |
CTD |
PMID:15697228 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
NR5A1 |
nuclear receptor subfamily 5 group A member 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Ethanol results in decreased expression of NR5A1 protein] |
CTD |
PMID:29524503 |
|
NCBI chr 9:124,481,236...124,507,399
Ensembl chr 9:124,481,236...124,507,420
|
|
G |
NXT1 |
nuclear transport factor 2 like export factor 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of NXT1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr20:23,350,791...23,354,771
Ensembl chr20:23,350,791...23,354,771
|
|
G |
OGN |
osteoglycin |
increases expression |
ISO |
Sirolimus results in increased expression of OGN mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 9:92,383,268...92,404,699
Ensembl chr 9:92,383,268...92,404,696
|
|
G |
OLR1 |
oxidized low density lipoprotein receptor 1 |
affects expression |
EXP |
Sirolimus affects the expression of OLR1 protein |
CTD |
PMID:17016853 |
|
NCBI chr12:10,158,301...10,176,266
Ensembl chr12:10,158,301...10,172,138
|
|
G |
OPTN |
optineurin |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] |
CTD |
PMID:25884947 |
|
NCBI chr10:13,100,082...13,138,308
Ensembl chr10:13,099,449...13,138,308
|
|
G |
OTUD7B |
OTU deubiquitinase 7B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]] Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in increased expression of ATG5 protein]] |
CTD |
PMID:36639017 |
|
NCBI chr 1:149,937,812...150,067,653
Ensembl chr 1:149,937,812...150,010,726
|
|
G |
OXA1L |
OXA1L mitochondrial inner membrane protein |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr14:22,766,688...22,773,042
Ensembl chr14:22,766,522...22,773,042
|
|
G |
PABPC1 |
poly(A) binding protein cytoplasmic 1 |
multiple interactions decreases expression |
EXP |
Sirolimus inhibits the reaction [EIF4G1 protein binds to PABPC1 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to PABPC1 mRNA] Sirolimus results in decreased expression of PABPC1 protein |
CTD |
PMID:25940091 |
|
NCBI chr 8:100,702,916...100,722,088
Ensembl chr 8:100,685,816...100,722,809
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
EXP ISO |
[Sirolimus co-treated with ovatodiolide] results in increased cleavage of PARP1 protein; ATG5 protein affects the reaction [Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; MCL1 protein inhibits the reaction [Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]]; Sirolimus inhibits the reaction [[[ABT-737 co-treated with Benzo(a)pyrene] co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in decreased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Ethanol results in increased cleavage of PARP1 protein]; Sirolimus inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [ovatodiolide results in increased cleavage of PARP1 protein] Sirolimus results in increased cleavage of PARP1 protein Sirolimus results in increased expression of PARP1 protein modified form [Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein; Sirolimus inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with Resveratrol] results in increased cleavage of PARP1 protein] Sirolimus promotes the reaction [Cadmium results in increased cleavage of PARP1 protein] |
CTD |
PMID:19682553 PMID:21410490 PMID:24304514 PMID:25307878 PMID:26825372 PMID:29111403 PMID:32802178 PMID:33002460 PMID:34374793 PMID:38000454 More...
|
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PAX8 |
paired box 8 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein] |
CTD |
PMID:21245298 |
|
NCBI chr 2:113,215,997...113,278,921
Ensembl chr 2:113,215,997...113,278,921
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[troglitazone co-treated with Sirolimus] results in decreased expression of PCK1 mRNA |
CTD |
PMID:10446394 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PCNA |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
EXP ISO |
[fulvestrant co-treated with Sirolimus] results in decreased expression of PCNA mRNA Sirolimus results in decreased expression of PCNA protein Sirolimus inhibits the reaction [IL2 protein results in increased expression of PCNA mRNA] |
CTD |
PMID:9151781 PMID:11355896 PMID:19016759 |
|
NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626
|
|
G |
PDCD4 |
programmed cell death 4 |
multiple interactions increases expression increases stability |
EXP ISO |
[resveratrol co-treated with Sirolimus] results in increased stability of PDCD4 protein; Sirolimus promotes the reaction [Tretinoin results in increased expression of PDCD4 protein] Sirolimus results in increased expression of PDCD4 mRNA; Sirolimus results in increased expression of PDCD4 protein Sirolimus results in increased stability of PDCD4 protein [Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein; PDCD4 mutant form inhibits the reaction [Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased expression of CTSK mRNA]]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 mRNA]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in decreased expression of PDCD4 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein] resveratrol inhibits the reaction [Sirolimus results in increased stability of PDCD4 protein] |
CTD |
PMID:17259349 PMID:24304514 PMID:24356939 PMID:26369790 |
|
NCBI chr10:110,871,928...110,900,006
Ensembl chr10:110,871,795...110,900,006
|
|
G |
PDGFB |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein] |
CTD |
PMID:15919668 |
|
NCBI chr22:39,223,359...39,244,982
Ensembl chr22:39,223,359...39,244,982
|
|
G |
PIK3CA |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
decreases response to substance multiple interactions increases activity increases expression |
EXP ISO |
Sirolimus results in decreased susceptibility to PIK3CA protein Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of CXCL8 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in decreased expression of HBP1 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of CCNE2 mRNA]; Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA]; Wortmannin inhibits the reaction [Sirolimus results in increased activity of PIK3CA protein] Sirolimus results in increased expression of PIK3CA mRNA Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA] |
CTD |
PMID:10373522 PMID:16227402 PMID:27542212 PMID:31522336 |
|
NCBI chr 3:179,148,126...179,240,093
Ensembl chr 3:179,148,114...179,240,093
|
|
G |
PIK3CB |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of PIK3CB mRNA Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 3:138,652,698...138,834,928
Ensembl chr 3:138,652,336...138,834,928
|
|
G |
PIK3CD |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
increases expression multiple interactions |
ISO |
Sirolimus results in increased expression of PIK3CD mRNA Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 1:9,627,258...9,729,114
Ensembl chr 1:9,629,889...9,729,114
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
decreases expression multiple interactions |
ISO |
Sirolimus results in decreased expression of PIK3CG mRNA Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CG mRNA] |
CTD |
PMID:31522336 |
|
NCBI chr 7:106,865,282...106,908,980
Ensembl chr 7:106,865,278...106,908,980
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [IRS1 protein binds to PIK3R1 protein] |
CTD |
PMID:17908691 |
|
NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821
|
|
G |
PIM1 |
Pim-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of PIM1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 6:37,170,152...37,175,428
Ensembl chr 6:37,170,152...37,175,428
|
|
G |
PINK1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PINK1 protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of PINK1 protein] |
CTD |
PMID:33823232 PMID:35405287 |
|
NCBI chr 1:20,633,458...20,651,511
Ensembl chr 1:20,633,458...20,651,511
|
|
G |
PKM |
pyruvate kinase M1/2 |
multiple interactions increases expression |
EXP |
[Sirolimus results in decreased activity of MTOR protein] which results in decreased expression of PKM protein; Curcumin inhibits the reaction [Sirolimus results in increased expression of PKM protein]; Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of PKM protein] |
CTD |
PMID:22574221 PMID:36336208 PMID:36640941 |
|
NCBI chr15:72,199,029...72,231,591
Ensembl chr15:72,199,029...72,231,819
|
|
G |
PKP4 |
plakophilin 4 |
increases expression |
ISO |
Sirolimus results in increased expression of PKP4 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 2:158,456,952...158,681,429
Ensembl chr 2:158,456,952...158,682,879
|
|
G |
PLCL1 |
phospholipase C like 1 (inactive) |
increases expression |
EXP |
Sirolimus results in increased expression of PLCL1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:197,804,593...198,149,863
Ensembl chr 2:197,804,593...198,572,581
|
|
G |
PMAIP1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
EXP |
[[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein |
CTD |
PMID:20686837 |
|
NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305
|
|
G |
PML |
PML nuclear body scaffold |
increases expression decreases response to substance increases localization |
EXP |
Sirolimus results in increased expression of PML protein PML protein results in decreased susceptibility to Sirolimus Sirolimus results in increased localization of PML protein |
CTD |
PMID:23440206 |
|
NCBI chr15:73,994,716...74,047,827
Ensembl chr15:73,994,673...74,047,827
|
|
G |
PMP22 |
peripheral myelin protein 22 |
increases metabolic processing |
ISO |
Sirolimus results in increased metabolism of PMP22 protein mutant form |
CTD |
PMID:20739560 |
|
NCBI chr17:15,229,779...15,265,326
Ensembl chr17:15,229,773...15,272,292
|
|
G |
PNPLA2 |
patatin like phospholipase domain containing 2 |
increases expression |
ISO |
Sirolimus results in increased expression of PNPLA2 mRNA; Sirolimus results in increased expression of PNPLA2 protein |
CTD |
PMID:20068142 |
|
NCBI chr11:818,914...825,573
Ensembl chr11:818,914...825,573
|
|
G |
PNRC1 |
proline rich nuclear receptor coactivator 1 |
increases expression |
EXP |
Sirolimus results in increased expression of PNRC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:89,080,751...89,085,160
Ensembl chr 6:89,080,751...89,085,160
|
|
G |
POLD2 |
DNA polymerase delta 2, accessory subunit |
decreases expression |
ISO |
Sirolimus results in decreased expression of POLD2 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 7:44,114,680...44,124,325
Ensembl chr 7:44,114,631...44,124,358
|
|
G |
POLR1H |
RNA polymerase I subunit H |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 6:30,060,062...30,064,907
Ensembl chr 6:30,058,899...30,064,909
|
|
G |
POSTN |
periostin |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 |
|
NCBI chr13:37,562,585...37,598,768
Ensembl chr13:37,562,583...37,598,844
|
|
G |
POU5F1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
Sirolimus results in increased expression of POU5F1 mRNA; Sirolimus results in increased expression of POU5F1 protein |
CTD |
PMID:21681844 |
|
NCBI chr 6:31,164,337...31,170,682
Ensembl chr 6:31,164,337...31,180,731
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]] |
CTD |
PMID:25045214 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARD |
peroxisome proliferator activated receptor delta |
multiple interactions |
ISO |
PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of ERN1 protein]; PPARD protein affects the reaction [[Sirolimus co-treated with HRAS protein] results in decreased expression of HSPA5 protein] |
CTD |
PMID:24898257 |
|
NCBI chr 6:35,342,558...35,428,178
Ensembl chr 6:35,342,558...35,428,191
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
affects expression multiple interactions decreases expression |
EXP ISO |
Sirolimus affects the expression of PPARG protein [Sirolimus co-treated with Cyclosporine] results in decreased expression of PPARG protein; [Sirolimus co-treated with Tacrolimus] results in increased expression of PPARG protein Sirolimus results in decreased expression of PPARG mRNA Sirolimus inhibits the reaction [Endrin results in increased expression of PPARG mRNA] |
CTD |
PMID:15358118 PMID:17016853 PMID:34801515 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]] Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:25045214 PMID:31499194 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PPL |
periplakin |
increases expression |
ISO |
Sirolimus results in increased expression of PPL mRNA |
CTD |
PMID:21865292 |
|
NCBI chr16:4,882,507...4,937,148
Ensembl chr16:4,882,507...4,960,741
|
|
G |
PPP1R1B |
protein phosphatase 1 regulatory inhibitor subunit 1B |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B mRNA]; Sirolimus inhibits the reaction [BDNF protein results in increased expression of PPP1R1B protein] |
CTD |
PMID:17209049 |
|
NCBI chr17:39,626,707...39,636,624
Ensembl chr17:39,626,740...39,636,626
|
|
G |
PPP2R1B |
protein phosphatase 2 scaffold subunit Abeta |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [PIK3CA protein modified form results in increased expression of PPP2R1B mRNA] |
CTD |
PMID:27542212 |
|
NCBI chr11:111,688,000...111,766,389
Ensembl chr11:111,726,908...111,766,389
|
|
G |
PRCP |
prolylcarboxypeptidase |
increases expression |
ISO |
Sirolimus results in increased expression of PRCP mRNA |
CTD |
PMID:21865292 |
|
NCBI chr11:82,822,936...82,901,644
Ensembl chr11:82,822,936...82,970,584
|
|
G |
PRF1 |
perforin 1 |
decreases expression |
EXP |
Sirolimus results in decreased expression of PRF1 protein |
CTD |
PMID:16477233 |
|
NCBI chr10:70,597,348...70,602,741
Ensembl chr10:70,597,348...70,602,759
|
|
G |
PRKAA1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Cadmium Chloride results in decreased phosphorylation of PRKAA1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 5:40,759,389...40,798,374
Ensembl chr 5:40,759,389...40,798,374
|
|
G |
PRKCA |
protein kinase C alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Estradiol results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:23000059 |
|
NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743
|
|
G |
PRKCD |
protein kinase C delta |
affects localization decreases phosphorylation multiple interactions |
EXP |
Sirolimus affects the localization of PRKCD protein Sirolimus results in decreased phosphorylation of PRKCD protein sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of PRKCD protein] |
CTD |
PMID:20082316 |
|
NCBI chr 3:53,161,209...53,192,717
Ensembl chr 3:53,156,009...53,192,717
|
|
G |
PRKCG |
protein kinase C gamma |
increases degradation multiple interactions |
EXP |
Sirolimus results in increased degradation of PRKCG protein mutant form Sirolimus inhibits the reaction [PRKCG protein mutant form binds to PRKCG protein mutant form] |
CTD |
PMID:20398063 |
|
NCBI chr19:53,881,094...53,907,652
Ensembl chr19:53,879,190...53,907,652
|
|
G |
PRKCH |
protein kinase C eta |
decreases response to substance multiple interactions |
EXP |
PRKCH results in decreased susceptibility to Sirolimus [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:16832347 |
|
NCBI chr14:61,187,468...61,550,976
Ensembl chr14:61,187,559...61,550,980
|
|
G |
PRKD2 |
protein kinase D2 |
multiple interactions |
EXP |
PRKD2 protein affects the reaction [Sirolimus results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:37951334 |
|
NCBI chr19:46,674,316...46,717,114
Ensembl chr19:46,674,275...46,717,127
|
|
G |
PRKN |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [[Particulate Matter co-treated with Rotenone] results in decreased expression of PRKN protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of PRKN protein] |
CTD |
PMID:33823232 PMID:35405287 |
|
NCBI chr 6:161,347,417...162,727,766
Ensembl chr 6:161,347,417...162,727,775
|
|
G |
PRLR |
prolactin receptor |
decreases expression |
ISO |
Sirolimus results in decreased expression of PRLR mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:35,048,756...35,230,487
Ensembl chr 5:35,048,756...35,230,487
|
|
G |
PRMT5 |
protein arginine methyltransferase 5 |
increases activity |
EXP |
Sirolimus results in increased activity of PRMT5 protein |
CTD |
PMID:31473880 |
|
NCBI chr14:22,920,529...22,929,376
Ensembl chr14:22,920,525...22,929,408
|
|
G |
PSMA1 |
proteasome 20S subunit alpha 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PSMA1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr11:14,504,876...14,643,662
Ensembl chr11:14,504,211...14,643,635
|
|
G |
PSMA4 |
proteasome 20S subunit alpha 4 |
decreases expression |
ISO |
Sirolimus results in decreased expression of PSMA4 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr15:78,540,405...78,552,417
Ensembl chr15:78,540,405...78,552,417
|
|
G |
PSMD11 |
proteasome 26S subunit, non-ATPase 11 |
decreases expression |
EXP |
Sirolimus results in decreased expression of PSMD11 mRNA; Sirolimus results in decreased expression of PSMD11 protein |
CTD |
PMID:15782132 |
|
NCBI chr17:32,444,510...32,483,319
Ensembl chr17:32,444,379...32,483,319
|
|
G |
PTEN |
phosphatase and tensin homolog |
multiple interactions decreases response to substance decreases expression |
EXP ISO |
[Decitabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with Sirolimus] results in increased expression of PTEN mRNA; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein] PTEN protein results in decreased susceptibility to Sirolimus Sirolimus results in decreased expression of PTEN protein Sirolimus inhibits the reaction [Cadmium Chloride results in decreased expression of PTEN protein] |
CTD |
PMID:18303120 PMID:18622747 PMID:19625624 PMID:21195169 PMID:31676321 |
|
NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930
|
|
G |
PTGER1 |
prostaglandin E receptor 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] |
CTD |
PMID:20335389 |
|
NCBI chr19:14,472,466...14,475,354
Ensembl chr19:14,472,466...14,475,354
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions affects expression |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of PTGS2 protein] Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 mRNA]; Sirolimus inhibits the reaction [Pilocarpine results in increased expression of PTGS2 protein] Sirolimus affects the expression of PTGS2 mRNA |
CTD |
PMID:22363816 PMID:23211629 PMID:24971338 PMID:36115647 |
|
NCBI chr 1:186,671,791...186,680,423
Ensembl chr 1:186,671,791...186,680,922
|
|
G |
PTK2 |
protein tyrosine kinase 2 |
decreases phosphorylation |
ISO |
Sirolimus results in decreased phosphorylation of PTK2 protein |
CTD |
PMID:19922502 |
|
NCBI chr 8:140,657,900...141,002,079
Ensembl chr 8:140,657,900...141,002,216
|
|
G |
PTPN5 |
protein tyrosine phosphatase non-receptor type 5 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr11:18,727,928...18,792,721
Ensembl chr11:18,727,928...18,792,721
|
|
G |
PTPRC |
protein tyrosine phosphatase receptor type C |
increases expression |
ISO |
Sirolimus results in increased expression of PTPRC mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 1:198,638,713...198,757,476
Ensembl chr 1:198,638,457...198,759,342
|
|
G |
PTTG1 |
PTTG1 regulator of sister chromatid separation, securin |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of PTTG1 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 5:160,421,855...160,428,744
Ensembl chr 5:160,421,855...160,428,739
|
|
G |
PYCARD |
PYD and CARD domain containing |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Trichloroethylene results in increased expression of PYCARD mRNA] |
CTD |
PMID:36849104 |
|
NCBI chr16:31,201,486...31,202,760
Ensembl chr16:31,201,486...31,203,450
|
|
G |
RAC1 |
Rac family small GTPase 1 |
decreases expression multiple interactions |
ISO |
Sirolimus results in decreased expression of RAC1 protein Sirolimus inhibits the reaction [Cadmium Chloride results in increased expression of RAC1 protein] |
CTD |
PMID:21195169 |
|
NCBI chr 7:6,374,527...6,403,967
Ensembl chr 7:6,374,527...6,403,967
|
|
G |
RAD51 |
RAD51 recombinase |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of RAD51 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340
|
|
G |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of RAF1 protein |
CTD |
PMID:15767555 |
|
NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201
|
|
G |
RB1 |
RB transcriptional corepressor 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
[Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein]; [Sirolimus co-treated with letrozole] results in decreased expression of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [tanespimycin co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RB1 protein] [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [KITL protein results in increased phosphorylation of RB1 protein] Sirolimus results in decreased phosphorylation of RB1 protein |
CTD |
PMID:7532117 PMID:8419408 PMID:10373522 PMID:10849422 PMID:12393642 PMID:12417722 PMID:12565877 PMID:14979923 PMID:15753396 PMID:15778701 PMID:17121904 PMID:17700525 PMID:20054642 PMID:21528311 More...
|
|
NCBI chr13:48,303,751...48,481,890
Ensembl chr13:48,303,744...48,599,436
|
|
G |
RBL1 |
RB transcriptional corepressor like 1 |
multiple interactions |
EXP |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein] |
CTD |
PMID:12417722 |
|
NCBI chr20:36,996,349...37,095,997
Ensembl chr20:36,996,349...37,095,997
|
|
G |
RBL2 |
RB transcriptional corepressor like 2 |
multiple interactions |
EXP |
[TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RBL2 protein] |
CTD |
PMID:10373522 PMID:12417722 |
|
NCBI chr16:53,434,471...53,491,648
Ensembl chr16:53,433,977...53,491,648
|
|
G |
RCAN1 |
regulator of calcineurin 1 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of RCAN1 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr21:34,516,442...34,615,113
Ensembl chr21:34,513,142...34,615,113
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [3,4,5-tri-O-(E)-caffeoylquinic acid analog results in increased phosphorylation of RELA protein]; Sirolimus inhibits the reaction [Doxorubicin results in increased activity of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] Sirolimus inhibits the reaction [Isoproterenol affects the localization of RELA protein]; Sirolimus inhibits the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:15571967 PMID:18789402 PMID:22003094 PMID:22363816 PMID:25045214 PMID:31586597 PMID:32156566 More...
|
|
NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090
|
|
G |
REN |
renin |
increases expression |
ISO |
Sirolimus results in increased expression of REN mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:204,154,819...204,166,337
Ensembl chr 1:204,154,819...204,190,324
|
|
G |
REST |
RE1 silencing transcription factor |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein] |
CTD |
PMID:21245298 |
|
NCBI chr 4:56,907,900...56,935,844
Ensembl chr 4:56,907,876...56,966,808
|
|
G |
RICTOR |
RPTOR independent companion of MTOR complex 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of RICTOR protein |
CTD |
PMID:18776922 |
|
NCBI chr 5:38,937,920...39,074,399
Ensembl chr 5:38,937,920...39,074,402
|
|
G |
RPL32 |
ribosomal protein L32 |
multiple interactions decreases expression |
EXP |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPL32 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPL32 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPL32 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr 3:12,834,485...12,841,582
Ensembl chr 3:12,834,485...12,841,582
|
|
G |
RPL7P26 |
ribosomal protein L7 pseudogene 26 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 6:17,530,828...17,531,457
Ensembl chr 6:17,530,899...17,531,652
|
|
G |
RPS20 |
ribosomal protein S20 |
multiple interactions decreases expression |
EXP |
LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS20 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS20 mRNA]; Sirolimus promotes the reaction [LARP1 protein binds to RPS20 mRNA] |
CTD |
PMID:25940091 |
|
NCBI chr 8:56,067,254...56,074,506
Ensembl chr 8:56,067,254...56,074,510
|
|
G |
RPS27L |
ribosomal protein S27 like |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter] |
CTD |
PMID:21245298 |
|
NCBI chr15:63,148,249...63,157,477
Ensembl chr15:63,125,872...63,158,021
|
|
G |
RPS6 |
ribosomal protein S6 |
multiple interactions decreases expression increases phosphorylation decreases phosphorylation |
EXP ISO |
[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6 protein; [Tetradecanoylphorbol Acetate results in increased activity of PRKCH protein] inhibits the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein]; LARP1 protein promotes the reaction [Sirolimus results in decreased expression of RPS6 protein]; Sirolimus inhibits the reaction [CXCL8 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [EIF4G1 protein binds to RPS6 mRNA]; Sirolimus inhibits the reaction [HRAS protein mutant form results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [INS protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus promotes the reaction [LARP1 protein binds to RPS6 mRNA]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] [Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [CSF1 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein]; Tacrolimus inhibits the reaction [Sirolimus inhibits the reaction [IL2 protein results in increased phosphorylation of RPS6 protein]] Sirolimus results in increased phosphorylation of RPS6 protein [resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:1614535 PMID:10373522 PMID:12939469 PMID:14502240 PMID:15297429 PMID:15778701 PMID:16832347 PMID:17121904 PMID:17606477 PMID:17908691 PMID:19478560 PMID:19625624 PMID:20038814 PMID:20068142 PMID:20169165 PMID:20863555 PMID:21036700 PMID:21212465 PMID:21245298 PMID:21450334 PMID:22069489 PMID:23363784 PMID:23396362 PMID:23440206 PMID:24304514 PMID:24375594 PMID:24386346 PMID:24392034 PMID:25940091 PMID:26621329 PMID:27255535 PMID:28342888 PMID:28574600 PMID:28790194 PMID:29748632 PMID:29793971 PMID:30619488 PMID:30687088 PMID:31051157 PMID:31676321 More...
|
|
NCBI chr 9:19,375,715...19,380,236
Ensembl chr 9:19,375,715...19,380,236
|
|
G |
RPS6KA1 |
ribosomal protein S6 kinase A1 |
increases phosphorylation affects localization multiple interactions |
EXP ISO |
Sirolimus results in increased phosphorylation of RPS6KA1 protein Sirolimus affects the localization of RPS6KA1 protein Sirolimus results in increased phosphorylation of and results in increased activity of RPS6KA1 protein |
CTD |
PMID:19151764 |
|
NCBI chr 1:26,529,761...26,575,025
Ensembl chr 1:26,529,761...26,575,030
|
|
G |
RPS6KA2 |
ribosomal protein S6 kinase A2 |
affects localization increases phosphorylation |
ISO |
Sirolimus affects the localization of RPS6KA2 protein Sirolimus results in increased phosphorylation of RPS6KA2 protein |
CTD |
PMID:19151764 |
|
NCBI chr 6:166,409,364...166,862,773
Ensembl chr 6:166,409,364...166,906,451
|
|
G |
RPS6KA3 |
ribosomal protein S6 kinase A3 |
affects localization increases phosphorylation |
ISO |
Sirolimus affects the localization of RPS6KA3 protein Sirolimus results in increased phosphorylation of RPS6KA3 protein |
CTD |
PMID:19151764 |
|
NCBI chr X:20,149,911...20,267,097
Ensembl chr X:20,149,911...20,267,519
|
|
G |
RPS6KB1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases activity decreases phosphorylation decreases expression increases phosphorylation increases expression |
EXP ISO |
[Dexamethasone co-treated with Sirolimus] inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; [Dexamethasone co-treated with Sirolimus] inhibits the reaction [IL6 protein results in increased phosphorylation of RPS6KB1 protein]; [Resveratrol co-treated with Sirolimus] results in increased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with Oxygen deficiency] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; [Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in decreased abundance of Superoxides; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased activity of IRS1 protein; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Acetaldehyde results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [cyanoginosin LR promotes the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [cyanoginosin LR results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Daunorubicin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS protein promotes the reaction [cyanoginosin LR results in increased expression of RPS6KB1 protein modified form]]; Sirolimus inhibits the reaction [INS protein results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [oxophenylarsine results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [PDGFB protein results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [puerarin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Testosterone results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [sodium arsenite results in decreased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; sodium arsenite promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6KB1 protein] [Sirolimus results in decreased activity of MTOR protein] which results in decreased activity of RPS6KB1 protein; Sirolimus results in decreased activity of RPS6KB1 protein [Sirolimus co-treated with Resveratrol] results in decreased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [chromium hexavalent ion results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [EDN1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Phenylephrine results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [Resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein [[manganese chloride results in increased abundance of Manganese] which co-treated with Sirolimus] results in decreased phosphorylation of RPS6KB1 protein; [Sirolimus co-treated with Resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BAX protein; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID mRNA; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased expression of BID protein; MRK 003 promotes the reaction [Sirolimus results in decreased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sirolimus inhibits the reaction [arsenite results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Cadmium Chloride results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Dronabinol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [INS1 protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [MTOR protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Pasteurella multocida toxin results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [Propranolol results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus promotes the reaction [MRK 003 results in decreased activity of RPS6KB1 protein]; Sirolimus promotes the reaction [Resveratrol results in decreased phosphorylation of RPS6KB1 protein] Sirolimus results in decreased phosphorylation of RPS6KB1 protein; Sirolimus results in decreased phosphorylation of S6K protein Sirolimus results in decreased expression of RPS6KB1 protein modified form Sirolimus results in increased phosphorylation of RPS6KB1 protein Sirolimus results in increased expression of RPS6KB1 protein modified form |
CTD |
PMID:12411397 PMID:14516795 PMID:14673156 PMID:15070696 PMID:15297429 PMID:15782132 PMID:15914125 PMID:15919668 PMID:16183647 PMID:16391472 PMID:16537399 PMID:16962100 PMID:17616671 PMID:17728140 PMID:17908691 PMID:18021293 PMID:18495876 PMID:18622747 PMID:19246562 PMID:19567381 PMID:19625624 PMID:19810018 PMID:19922502 PMID:20169165 PMID:20574048 PMID:20682991 PMID:20880397 PMID:20936651 PMID:21036700 PMID:21168265 PMID:21321189 PMID:21357504 PMID:21544240 PMID:21858812 PMID:21898527 PMID:21933187 PMID:21984483 PMID:22215663 PMID:22574221 PMID:22863860 PMID:22869613 PMID:23111315 PMID:23255002 PMID:24299490 PMID:24304514 PMID:24375594 PMID:25307878 PMID:25663935 PMID:25758096 PMID:25884947 PMID:25940091 PMID:26282490 PMID:26369790 PMID:26506538 PMID:26621329 PMID:27286880 PMID:27579538 PMID:27796870 PMID:28984034 PMID:29650965 PMID:30236763 PMID:30555576 PMID:30661989 PMID:31051157 PMID:31645432 PMID:31676321 PMID:31690173 PMID:32044396 PMID:32329240 PMID:32802178 PMID:33124469 PMID:33838154 PMID:34536393 PMID:34717917 PMID:35445903 PMID:35985552 PMID:37939893 More...
|
|
NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574
|
|
G |
RPS6KB2 |
ribosomal protein S6 kinase B2 |
multiple interactions decreases activity |
EXP |
MTOR protein inhibits the reaction [Sirolimus results in decreased activity of RPS6KB2 protein]; Sirolimus inhibits the reaction [Phosphatidic Acids results in increased activity of RPS6KB2 protein] |
CTD |
PMID:12087098 |
|
NCBI chr11:67,428,494...67,435,401
Ensembl chr11:67,428,460...67,435,401
|
|
G |
RPTOR |
regulatory associated protein of MTOR complex 1 |
multiple interactions |
EXP |
[Sirolimus inhibits the reaction [MTOR protein binds to RPTOR protein]] which results in increased expression of MAP1LC3A protein alternative form; [Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein]] which results in increased activity of AR protein; RPTOR protein inhibits the reaction [Sirolimus results in increased activity of AR protein]; Sirolimus inhibits the reaction [[MTOR protein binds to RAPTOR protein] which binds to LARP1 protein]; Sirolimus inhibits the reaction [Orotic Acid results in decreased phosphorylation of RPTOR protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein binds to MLST8 protein]; Sirolimus results in decreased activity of [MTOR protein binds to RPTOR protein] |
CTD |
PMID:18776922 PMID:19505958 PMID:21742779 PMID:22863860 PMID:25940091 |
|
NCBI chr17:80,544,838...80,966,368
Ensembl chr17:80,544,819...80,966,371
|
|
G |
RRAD |
RRAD, Ras related glycolysis inhibitor and calcium channel regulator |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter] |
CTD |
PMID:21245298 |
|
NCBI chr16:66,921,685...66,925,535
Ensembl chr16:66,921,685...66,925,535
|
|
G |
RTN4 |
reticulon 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4 protein] |
CTD |
PMID:26648565 |
|
NCBI chr 2:54,972,189...55,137,831
Ensembl chr 2:54,972,187...55,112,621
|
|
G |
RTN4R |
reticulon 4 receptor |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of RTN4R protein] |
CTD |
PMID:26648565 |
|
NCBI chr22:20,241,415...20,268,318
Ensembl chr22:20,241,415...20,283,246
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 mRNA]]; Sirolimus inhibits the reaction [Calcitriol inhibits the reaction [Glucose results in decreased expression of RUNX2 protein]] |
CTD |
PMID:23111315 PMID:33450223 |
|
NCBI chr 6:45,328,330...45,551,082
Ensembl chr 6:45,328,157...45,664,349
|
|
G |
S100A4 |
S100 calcium binding protein A4 |
decreases expression |
ISO |
Sirolimus results in decreased expression of S100A4 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:153,543,621...153,545,806
Ensembl chr 1:153,543,613...153,550,136
|
|
G |
S100G |
S100 calcium binding protein G |
increases expression |
ISO |
Sirolimus results in increased expression of S100G mRNA |
CTD |
PMID:21865292 |
|
NCBI chr X:16,650,158...16,654,670
Ensembl chr X:16,650,158...16,654,670
|
|
G |
S1PR1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
EXP |
Sirolimus results in increased expression of S1PR1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:101,236,899...101,242,313
Ensembl chr 1:101,236,865...101,243,713
|
|
G |
SCARB2 |
scavenger receptor class B member 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of SCARB2 mRNA |
CTD |
PMID:17016853 |
|
NCBI chr 4:76,158,737...76,234,532
Ensembl chr 4:76,158,737...76,234,536
|
|
G |
SCARNA23 |
small Cajal body-specific RNA 23 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SCARNA23 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr X:24,744,441...24,744,570
Ensembl chr X:24,744,441...24,744,570
|
|
G |
SCD |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr10:100,347,233...100,364,826
Ensembl chr10:100,347,233...100,364,826
|
|
G |
SEMA3A |
semaphorin 3A |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [chromium hexavalent ion results in increased expression of SEMA3A protein] |
CTD |
PMID:30236763 |
|
NCBI chr 7:83,955,777...84,492,725
Ensembl chr 7:83,955,777...84,492,724
|
|
G |
SEMA3C |
semaphorin 3C |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:80,742,538...80,922,389
Ensembl chr 7:80,742,538...80,922,359
|
|
G |
SERPINA1 |
serpin family A member 1 |
affects localization |
EXP |
Sirolimus affects the localization of SERPINA1 protein |
CTD |
PMID:20511674 |
|
NCBI chr14:94,376,747...94,390,635
Ensembl chr14:94,376,747...94,390,693
|
|
G |
SERPINA3 |
serpin family A member 3 |
increases expression |
ISO |
Sirolimus results in increased expression of SERPINA3N mRNA |
CTD |
PMID:21865292 |
|
NCBI chr14:94,612,391...94,624,053
Ensembl chr14:94,612,384...94,624,055
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA] Sirolimus inhibits the reaction [Ethylene Chlorohydrin promotes the reaction [Lipopolysaccharides results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:21245298 PMID:31499194 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SESN2 |
sestrin 2 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of SESN2 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr 1:28,259,518...28,282,491
Ensembl chr 1:28,259,518...28,282,491
|
|
G |
SHANK3 |
SH3 and multiple ankyrin repeat domains 3 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [phenanthrene results in decreased expression of SHANK3 mRNA] |
CTD |
PMID:34453960 |
|
NCBI chr22:50,672,823...50,733,212
Ensembl chr22:50,674,408...50,733,212
|
|
G |
SHISA2 |
shisa family member 2 |
increases expression |
EXP |
Sirolimus results in increased expression of SHISA2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:26,044,597...26,052,016
Ensembl chr13:26,044,597...26,052,016
|
|
G |
SIRT1 |
sirtuin 1 |
multiple interactions decreases expression increases expression increases response to substance |
EXP ISO |
[(+)-JQ1 compound co-treated with Sirolimus] results in decreased expression of SIRT1 protein; Aspirin inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein]; cilostazol inhibits the reaction [Sirolimus results in decreased expression of SIRT1 protein] Sirolimus inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] Sirolimus results in increased expression of SIRT1 protein SIRT1 protein results in increased susceptibility to Sirolimus |
CTD |
PMID:19520256 PMID:22561310 PMID:25307878 |
|
NCBI chr10:67,884,656...67,918,390
Ensembl chr10:67,884,656...67,918,390
|
|
G |
SIRT2 |
sirtuin 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr19:38,878,555...38,899,618
Ensembl chr19:38,878,555...38,899,862
|
|
G |
SIRT4 |
sirtuin 4 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]] Sirolimus affects the reaction [SIRT4 protein affects the reaction [Doxorubicin affects the expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of MTOR protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BAX protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased expression of BECN1 protein]]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:35134463 |
|
NCBI chr12:120,291,780...120,313,249
Ensembl chr12:120,302,316...120,313,249
|
|
G |
SKP2 |
S-phase kinase associated protein 2 |
decreases expression |
EXP |
Sirolimus results in decreased expression of SKP2 protein |
CTD |
PMID:21092744 |
|
NCBI chr 5:36,152,111...36,193,530
Ensembl chr 5:36,151,989...36,196,849
|
|
G |
SLC12A1 |
solute carrier family 12 member 1 |
multiple interactions decreases expression |
ISO |
rosiglitazone inhibits the reaction [Sirolimus results in decreased expression of SLC12A1 protein] |
CTD |
PMID:19656910 |
|
NCBI chr15:48,206,302...48,304,078
Ensembl chr15:48,178,438...48,304,078
|
|
G |
SLC12A3 |
solute carrier family 12 member 3 |
increases expression |
ISO |
Sirolimus results in increased expression of SLC12A3 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr16:56,865,207...56,915,850
Ensembl chr16:56,865,207...56,915,850
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [rosiglitazone results in increased expression of and results in increased activity of SLC15A1 protein] |
CTD |
PMID:22108913 |
|
NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672
|
|
G |
SLC16A1 |
solute carrier family 16 member 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SLC16A1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 1:112,911,847...112,956,196
Ensembl chr 1:112,911,847...112,957,593
|
|
G |
SLC22A13 |
solute carrier family 22 member 13 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SLC22A13 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 3:38,265,812...38,278,757
Ensembl chr 3:38,265,812...38,278,757
|
|
G |
SLC2A1 |
solute carrier family 2 member 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC2A1 protein]; Sirolimus inhibits the reaction [ATG4B protein results in increased expression of SLC2A1 protein] |
CTD |
PMID:36336208 |
|
NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893
|
|
G |
SLC31A1 |
solute carrier family 31 member 1 |
multiple interactions |
EXP |
Sirolimus affects the reaction [SLC31A1 protein affects the expression of BAX protein]; Sirolimus affects the reaction [SLC31A1 protein affects the expression of BCL2 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of AKT1 protein]; Sirolimus affects the reaction [SLC31A1 protein affects the phosphorylation of MTOR protein] |
CTD |
PMID:37290678 |
|
NCBI chr 9:113,221,544...113,264,492
Ensembl chr 9:113,221,544...113,264,492
|
|
G |
SLC5A1 |
solute carrier family 5 member 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SLC5A1 mRNA |
CTD |
PMID:21865292 |
|
NCBI chr22:32,043,261...32,113,029
Ensembl chr22:32,043,261...32,113,029
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
increases expression |
ISO |
Sirolimus results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:11589784 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SMIM14 |
small integral membrane protein 14 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 4:39,546,336...39,638,865
Ensembl chr 4:39,546,336...39,638,902
|
|
G |
SNAI1 |
snail family transcriptional repressor 1 |
multiple interactions increases expression |
EXP ISO |
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of SNAI1 mRNA] Sirolimus results in increased expression of SNAI1 protein NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of SNAI1 protein]; Sirolimus promotes the reaction [Dibutyl Phthalate results in increased expression of SNAI1 mRNA] |
CTD |
PMID:28624451 PMID:28888487 PMID:30053495 |
|
NCBI chr20:49,982,980...49,988,886
Ensembl chr20:49,982,980...49,988,886
|
|
G |
SNCA |
synuclein alpha |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Paraquat results in increased expression of SNCA protein] |
CTD |
PMID:32306690 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
SOD1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [sodium arsenite results in decreased expression of SOD1 protein] |
CTD |
PMID:38574842 |
|
NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931
|
|
G |
SOD2 |
superoxide dismutase 2 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SOD2 protein |
CTD |
PMID:30905858 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SOX2 |
SRY-box transcription factor 2 |
increases expression |
ISO |
Sirolimus results in increased expression of SOX2 mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 3:181,711,925...181,714,436
Ensembl chr 3:181,711,925...181,714,436
|
|
G |
SOX9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SOX9 protein |
CTD |
PMID:34536393 |
|
NCBI chr17:72,121,020...72,126,416
Ensembl chr17:72,121,020...72,126,416
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] |
CTD |
PMID:31051157 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions decreases expression increases expression increases degradation |
ISO EXP |
[Sirolimus co-treated with Cadmium] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with gelsenicine] results in decreased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; CD38 mutant form inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus affects the reaction [SIRT4 protein affects the reaction [Doxorubicin affects the expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in decreased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Ethanol results in decreased expression of SQSTM1 protein] [Sirolimus co-treated with cadmium acetate] results in decreased expression of SQSTM1 mRNA; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [manganese chloride results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [OTUD7B protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus inhibits the reaction [Particulate Matter results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [SIRT4 protein inhibits the reaction [Doxorubicin results in decreased expression of SQSTM1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]] [AICA ribonucleotide co-treated with Sirolimus] results in increased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; Curcumin inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Resveratrol inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [honokiol results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [lead acetate results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [ovatodiolide results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; Sirolimus promotes the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased degradation of SQSTM1 protein] Sirolimus results in increased expression of SQSTM1 protein Sirolimus results in increased degradation of SQSTM1 protein |
CTD |
PMID:19773376 PMID:24238063 PMID:24304514 PMID:25884947 PMID:28025121 PMID:29128638 PMID:29218509 PMID:29222055 PMID:29505745 PMID:29518472 PMID:29781141 PMID:29870746 PMID:30338810 PMID:31676321 PMID:31690173 PMID:32430275 PMID:32645460 PMID:33070465 PMID:33359579 PMID:33550458 PMID:33684387 PMID:34281243 PMID:34536393 PMID:34842334 PMID:35134463 PMID:35175747 PMID:35588915 PMID:36639017 PMID:36640941 PMID:36708882 PMID:37148155 PMID:38000454 PMID:38237716 PMID:38604309 More...
|
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of EGFR protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK1 protein; [Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein] which results in increased phosphorylation of MAPK3 protein; Sirolimus inhibits the reaction [[Ethylene Chlorohydrin co-treated with Lipopolysaccharides] results in decreased phosphorylation of SRC protein]; Sirolimus results in increased phosphorylation of and results in increased activity of SRC protein |
CTD |
PMID:19151764 PMID:31499194 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of SREBF1 mRNA |
CTD |
PMID:15358118 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SRR |
serine racemase |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] |
CTD |
PMID:24012499 |
|
NCBI chr17:2,303,378...2,325,264
Ensembl chr17:2,303,383...2,325,260
|
|
G |
STAR |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Polystyrenes analog results in decreased expression of STAR protein] |
CTD |
PMID:36709824 |
|
NCBI chr 8:38,142,700...38,150,952
Ensembl chr 8:38,142,700...38,150,992
|
|
G |
STARD10 |
StAR related lipid transfer domain containing 10 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr11:72,754,729...72,794,047
Ensembl chr11:72,754,729...72,794,047
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Sirolimus results in decreased phosphorylation of STAT3 protein Sirolimus inhibits the reaction [IFNG protein results in decreased phosphorylation of STAT3 protein] Sirolimus inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of STAT3 protein] |
CTD |
PMID:16391472 PMID:16427044 PMID:20038814 PMID:26648565 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
STS |
steroid sulfatase |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:7,147,290...7,354,641
Ensembl chr X:7,147,237...7,804,358
|
|
G |
SUV39H1 |
SUV39H1 histone lysine methyltransferase |
multiple interactions |
EXP |
[TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein |
CTD |
PMID:31676321 |
|
NCBI chr X:48,695,554...48,709,016
Ensembl chr X:48,695,554...48,709,016
|
|
G |
SYN1 |
synapsin I |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Ketamine results in increased expression of SYN1 protein] |
CTD |
PMID:33022268 |
|
NCBI chr X:47,571,901...47,619,857
Ensembl chr X:47,571,901...47,619,857
|
|
G |
SYT1 |
synaptotagmin 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr12:78,863,982...79,452,008
Ensembl chr12:78,863,993...79,452,008
|
|
G |
TAF12 |
TATA-box binding protein associated factor 12 |
decreases expression |
ISO |
Sirolimus results in decreased expression of TAF12 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 1:28,602,850...28,648,269
Ensembl chr 1:28,587,829...28,648,291
|
|
G |
TAL1 |
TAL bHLH transcription factor 1, erythroid differentiation factor |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein] |
CTD |
PMID:21245298 |
|
NCBI chr 1:47,216,290...47,232,335
Ensembl chr 1:47,216,290...47,232,225
|
|
G |
TARDBP |
TAR DNA binding protein |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of and affects the localization of TARDBP protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein] |
CTD |
PMID:25884947 PMID:35405287 |
|
NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,344...11,030,528
|
|
G |
TARS1 |
threonyl-tRNA synthetase 1 |
decreases expression |
ISO |
Sirolimus results in decreased expression of TARS1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 5:33,440,696...33,468,091
Ensembl chr 5:33,440,696...33,468,091
|
|
G |
TAX1BP1 |
Tax1 binding protein 1 |
increases expression |
ISO |
Sirolimus results in increased expression of TAX1BP1 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 7:27,739,373...27,829,767
Ensembl chr 7:27,739,331...27,844,564
|
|
G |
TCF19 |
transcription factor 19 |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of TCF19 mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 6:31,158,589...31,164,215
Ensembl chr 6:31,158,331...31,167,159
|
|
G |
TEAD1 |
TEA domain transcription factor 1 |
multiple interactions |
EXP |
Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein] |
CTD |
PMID:21245298 |
|
NCBI chr11:12,674,421...12,944,737
Ensembl chr11:12,674,421...12,944,737
|
|
G |
TERT |
telomerase reverse transcriptase |
decreases expression |
EXP |
Sirolimus results in decreased expression of TERT mRNA; Sirolimus results in decreased expression of TERT protein |
CTD |
PMID:12939469 PMID:16455087 PMID:17996122 PMID:20863555 |
|
NCBI chr 5:1,253,167...1,295,068
Ensembl chr 5:1,253,147...1,295,068
|
|
G |
TFEB |
transcription factor EB |
affects localization increases expression multiple interactions |
EXP |
Sirolimus affects the localization of TFEB protein Sirolimus results in increased expression of TFEB protein Sirolimus inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in decreased expression of TFEB protein] |
CTD |
PMID:28366621 PMID:37951334 PMID:38574842 |
|
NCBI chr 6:41,683,978...41,736,223
Ensembl chr 6:41,683,978...41,736,259
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions increases response to substance decreases expression |
EXP ISO |
[Sirolimus binds to FKBP1A protein] which results in increased activity of TGFB1 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1A protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [Sirolimus co-treated with TGFB1 protein] results in increased expression of CDKN1A protein; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL1 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] inhibits the reaction [[E2F4 protein binds to RBL2 protein] which binds to CDK2 protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1A protein]; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased activity of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of CDK2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] results in increased expression of CDKN1A protein; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in decreased expression of IL6 protein; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 mRNA; [TGFB1 protein modified form co-treated with Sirolimus] results in increased expression of FOXP3 protein [Sirolimus co-treated with TGFB1 protein] affects the localization of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] affects the localization of CDKN1B protein; [Sirolimus co-treated with TGFB1 protein] promotes the reaction [CDKN1B protein binds to CDK2 protein]; [Sirolimus co-treated with TGFB1 protein] results in decreased activity of CDK2 protein; [Sirolimus co-treated with TGFB1 protein] results in decreased phosphorylation of RB1 protein; [TGFB1 protein co-treated with Sirolimus] promotes the reaction [CDK2 protein binds to CDKN1B protein]; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein; [TGFB1 protein co-treated with Sirolimus] results in decreased phosphorylation of RB1 protein; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [[Cadmium Chloride co-treated with TGFB1 protein] results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP8 protein]]; Sirolimus inhibits the reaction [TGFB1 protein inhibits the reaction [Cadmium Chloride results in increased expression of CASP9 protein]]; Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CG mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; Sirolimus inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA] TGFB1 protein results in increased susceptibility to Sirolimus Sirolimus inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Sirolimus inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; Sirolimus inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] Sirolimus results in decreased expression of TGFB1 mRNA |
CTD |
PMID:10535884 PMID:12417722 PMID:14979923 PMID:17050028 PMID:17550925 PMID:17700525 PMID:20844194 PMID:24971338 PMID:28342888 PMID:31522336 PMID:33720480 PMID:35405287 More...
|
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TGFBR3 |
transforming growth factor beta receptor 3 |
increases expression |
ISO |
Sirolimus results in increased expression of TGFBR3 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr 1:91,680,343...91,906,002
Ensembl chr 1:91,680,343...91,906,335
|
|
G |
TGM2 |
transglutaminase 2 |
decreases expression |
ISO |
Sirolimus results in decreased expression of TGM2 mRNA |
CTD |
PMID:11355896 |
|
NCBI chr20:38,127,385...38,168,475
Ensembl chr20:38,127,385...38,166,578
|
|
G |
TIMELESS |
timeless circadian regulator |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of TIMELESS mRNA |
CTD |
PMID:19016759 |
|
NCBI chr12:56,416,363...56,449,426
Ensembl chr12:56,416,363...56,449,426
|
|
G |
TIMP3 |
TIMP metallopeptidase inhibitor 3 |
decreases expression |
EXP |
Sirolimus results in decreased expression of TIMP3 mRNA; Sirolimus results in decreased expression of TIMP3 protein |
CTD |
PMID:21742783 |
|
NCBI chr22:32,801,705...32,863,041
Ensembl chr22:32,801,705...32,863,041
|
|
G |
TMEM14C |
transmembrane protein 14C |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 6:10,723,070...10,731,127
Ensembl chr 6:10,722,915...10,731,129
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions increases expression decreases secretion decreases expression |
EXP ISO |
[Sirolimus co-treated with TNF protein] results in decreased expression of SQSTM1 protein; [Sirolimus co-treated with TNF protein] results in increased expression of ATG5 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of ATG7 mRNA; [Sirolimus co-treated with TNF protein] results in increased expression of BECN1 protein; [TNF protein co-treated with Sirolimus co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in increased ubiquitination of SUV39H1 protein; [TNF protein co-treated with Sirolimus] results in decreased expression of SUV39H1 protein; Sirolimus inhibits the reaction [[trovafloxacin co-treated with TNF protein] results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of PTEN protein]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; Sirolimus inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [TNF protein results in increased expression of F3 protein] Sirolimus results in increased expression of TNF [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; [Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [Resveratrol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; Sirolimus inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Poloxalene results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of MTOR protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6 protein] Sirolimus results in decreased secretion of TNF protein Sirolimus results in decreased expression of TNF mRNA Sirolimus inhibits the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Sirolimus inhibits the reaction [Silicon Dioxide results in increased expression of TNF protein]; Sirolimus inhibits the reaction [TNF protein results in increased phosphorylation of RPS6KB1 protein]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADL mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of ACADM mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of CPT2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARA protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in decreased expression of PPARGC1A protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL1B protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of IL2 protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of MYH7 mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of NPPB mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased expression of TNF protein]]; TNF protein inhibits the reaction [Sirolimus inhibits the reaction [Isoproterenol results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:12531798 PMID:14502240 PMID:16314788 PMID:19567381 PMID:19810018 PMID:21600178 PMID:22069489 PMID:22363816 PMID:24971338 PMID:25045214 PMID:31332898 PMID:31586597 PMID:31676321 PMID:33609687 PMID:33720480 PMID:36799065 More...
|
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of EIF4EBP1 protein]; Sirolimus inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:14502240 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions decreases phosphorylation increases expression |
EXP ISO |
[Sirolimus results in decreased activity of MTOR protein] which results in decreased phosphorylation of TP53 protein; Sirolimus inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]; Sirolimus promotes the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]; Sirolimus promotes the reaction [TP53 protein results in increased expression of BBC3 protein] Sirolimus results in decreased phosphorylation of TP53 protein Sirolimus results in increased expression of TP53 mRNA Sirolimus inhibits the reaction [arsenite results in increased expression of and results in increased phosphorylation of TRP53 protein] |
CTD |
PMID:11602639 PMID:19560264 PMID:23396362 PMID:24971338 PMID:30555576 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TP63 |
tumor protein p63 |
decreases expression |
EXP ISO |
Sirolimus results in decreased expression of TP63 protein Sirolimus results in decreased expression of TRP63 protein |
CTD |
PMID:20038814 |
|
NCBI chr 3:189,596,746...189,897,276
Ensembl chr 3:189,631,389...189,897,276
|
|
G |
TP73 |
tumor protein p73 |
multiple interactions increases expression |
EXP |
[[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of BBC3 protein; [[Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein] which results in increased expression of PMAIP1 protein; [Sirolimus co-treated with Cisplatin] results in increased expression of TP73 protein; Sirolimus inhibits the reaction [TP73 protein affects the activity of HEN1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of HOXA9 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of TAL1 protein]; Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of ACER2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of JMY mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of MIR181A2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of NR1H4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of RPL7P26 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SCD mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of SERPINE1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ABTB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of AOPEP mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CAV3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CCNG2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of CHRNB3 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of DEPTOR mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FAXDC2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FBXO32 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FGF7 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FOLR1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of FTL mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of ING4 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MBNL2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MTURN mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYLK mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of MYOF mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of NMU mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of OXA1L mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of POLR1H mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SEMA3C mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SIRT2 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SMIM14 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of STARD10 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of SYT1 mRNA]; Sirolimus inhibits the reaction [TP73 protein results in increased expression of TMEM14C mRNA]; Sirolimus promotes the reaction [TP73 protein affects the activity of GCM2 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of PAX8 protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of REST protein]; Sirolimus promotes the reaction [TP73 protein affects the activity of TEAD1 protein]; Sirolimus promotes the reaction [TP73 protein binds to MDM2 promoter]; Sirolimus promotes the reaction [TP73 protein binds to RPS27L promoter]; Sirolimus promotes the reaction [TP73 protein binds to RRAD promoter]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR151 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR190A mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR29C mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR324 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR379 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR433 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR503 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR508 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR650 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR654 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR758 mRNA]; TP73 protein promotes the reaction [Sirolimus results in increased expression of MIR760 mRNA]; TP73 protein results in increased susceptibility to [Sirolimus co-treated with Cisplatin] Sirolimus results in increased expression of TP73 protein |
CTD |
PMID:20686837 PMID:21245298 |
|
NCBI chr 1:3,652,516...3,736,201
Ensembl chr 1:3,652,516...3,736,201
|
|
G |
TPP2 |
tripeptidyl peptidase 2 |
multiple interactions |
ISO |
Sirolimus promotes the reaction [Etoposide affects the localization of TPP2 protein] |
CTD |
PMID:20643100 |
|
NCBI chr13:102,596,986...102,679,958
Ensembl chr13:102,596,958...102,679,958
|
|
G |
TRIB3 |
tribbles pseudokinase 3 |
multiple interactions |
EXP |
[(+)-JQ1 compound co-treated with Sirolimus] affects the expression of TRIB3 mRNA |
CTD |
PMID:25307878 |
|
NCBI chr20:380,760...397,559
Ensembl chr20:362,835...397,559
|
|
G |
TRPM6 |
transient receptor potential cation channel subfamily M member 6 |
multiple interactions increases expression |
ISO |
rosiglitazone inhibits the reaction [Sirolimus results in increased expression of TRPM6 protein] |
CTD |
PMID:19656910 |
|
NCBI chr 9:74,722,495...74,887,921
Ensembl chr 9:74,722,495...74,888,094
|
|
G |
TSC1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in decreased phosphorylation of GSK3B protein]; Sirolimus inhibits the reaction [TSC1 gene mutant form results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:18495876 |
|
NCBI chr 9:132,891,349...132,945,378
Ensembl chr 9:132,891,348...132,946,874
|
|
G |
TSC2 |
TSC complex subunit 2 |
multiple interactions |
ISO EXP |
Sirolimus inhibits the reaction [resveratrol inhibits the reaction [TSC2 protein results in decreased phosphorylation of RPS6KB1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of DDIT3 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of ERO1A mRNA]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased expression of HMOX1 protein]; TSC2 protein inhibits the reaction [[Sirolimus co-treated with resveratrol] results in increased cleavage of PARP1 protein] Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 mRNA]; Sirolimus inhibits the reaction [TNF protein results in decreased expression of TSC2 protein]; TSC2 gene mutant form promotes the reaction [[Resveratrol co-treated with Sirolimus] results in decreased phosphorylation of RPS6 protein]; TSC2 gene mutant form promotes the reaction [Sirolimus results in decreased phosphorylation of RPS6 protein] [resveratrol co-treated with Sirolimus] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; [Sirolimus co-treated with resveratrol] inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; [Sirolimus co-treated with resveratrol] promotes the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; resveratrol inhibits the reaction [Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in decreased phosphorylation of AKT1S1 protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of EIF4B protein]; Sirolimus inhibits the reaction [TSC2 gene mutant form results in increased phosphorylation of RPS6KB1 protein]; TSC2 gene mutant form promotes the reaction [[Sirolimus co-treated with resveratrol] results in increased stability of PDCD4 protein] |
CTD |
PMID:19420259 PMID:24304514 PMID:31676321 |
|
NCBI chr16:2,047,985...2,089,491
Ensembl chr16:2,047,967...2,089,491
|
|
G |
TTK |
TTK protein kinase |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of TTK mRNA |
CTD |
PMID:19016759 |
|
NCBI chr 6:80,004,649...80,042,527
Ensembl chr 6:80,003,887...80,042,527
|
|
G |
TYMS |
thymidylate synthetase |
decreases expression |
EXP |
Sirolimus results in decreased expression of TYMS; Sirolimus results in decreased expression of TYMS mRNA |
CTD |
PMID:19764996 PMID:20682991 |
|
NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
|
|
G |
ULK1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions increases expression |
ISO EXP |
Sirolimus affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein] Sirolimus promotes the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein]; Sirolimus promotes the reaction [Alpha-Amanitin results in increased expression of ULK1 protein] Sirolimus results in increased expression of ULK1 protein |
CTD |
PMID:29128638 PMID:29518472 PMID:33070465 PMID:37329965 |
|
NCBI chr12:131,894,622...131,923,150
Ensembl chr12:131,894,622...131,923,150
|
|
G |
URI1 |
URI1 prefoldin like chaperone |
decreases response to substance |
EXP |
URI1 results in decreased susceptibility to Sirolimus |
CTD |
PMID:21397856 |
|
NCBI chr19:29,923,657...30,016,612
Ensembl chr19:29,923,644...30,016,612
|
|
G |
USP7 |
ubiquitin specific peptidase 7 |
multiple interactions |
EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein]]; Sirolimus inhibits the reaction [[[sodium arsenite results in increased abundance of Arsenic] which co-treated with Benzo(a)pyrene] results in increased expression of USP7 protein] |
CTD |
PMID:32802178 |
|
NCBI chr16:8,892,097...8,963,906
Ensembl chr16:8,892,097...8,975,328
|
|
G |
VASN |
vasorin |
decreases expression |
ISO |
Sirolimus results in decreased expression of VASN mRNA |
CTD |
PMID:17028423 |
|
NCBI chr16:4,371,848...4,383,538
Ensembl chr16:4,371,848...4,383,538
|
|
G |
VCAN |
versican |
increases expression |
ISO |
Sirolimus results in increased expression of VCAN mRNA |
CTD |
PMID:21865292 |
|
NCBI chr 5:83,471,744...83,582,302
Ensembl chr 5:83,471,618...83,582,303
|
|
G |
VCP |
valosin containing protein |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein] Sirolimus inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of MTOR protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of RPS6KB1 protein modified form]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [VCP protein mutant form results in increased expression of TARDBP protein] |
CTD |
PMID:25884947 |
|
NCBI chr 9:35,056,064...35,072,625
Ensembl chr 9:35,053,928...35,072,668
|
|
G |
VEGFA |
vascular endothelial growth factor A |
multiple interactions decreases expression |
EXP ISO |
[Curcumin analog co-treated with Sirolimus] inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [4-hydroxyestradiol results in increased expression of VEGFA protein]; Sirolimus inhibits the reaction [IGF1 protein results in increased secretion of VEGFA protein]; Sirolimus inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA] Sirolimus results in decreased expression of VEGFA mRNA Sirolimus results in decreased expression of VEGFA protein [Sirolimus co-treated with Hydrogen Peroxide] results in increased expression of VEGFA mRNA Sirolimus inhibits the reaction [cyanoginosin LR results in increased expression of VEGFA protein] |
CTD |
PMID:15050414 PMID:15930297 PMID:16682453 PMID:17968710 PMID:20554536 PMID:24971338 PMID:31332898 PMID:36115647 More...
|
|
NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VIM |
vimentin |
multiple interactions |
EXP ISO |
Sirolimus inhibits the reaction [sodium arsenite results in increased expression of VIM protein] NFE2L2 protein promotes the reaction [Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein]]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM mRNA]; Sirolimus inhibits the reaction [Paraquat results in increased expression of VIM protein] |
CTD |
PMID:28624451 PMID:28888487 |
|
NCBI chr10:17,228,241...17,237,593
Ensembl chr10:17,228,241...17,237,593
|
|
G |
WT1 |
WT1 transcription factor |
decreases expression |
EXP |
Sirolimus results in decreased expression of WT1 mRNA; Sirolimus results in decreased expression of WT1 protein; Sirolimus results in decreased expression of WT1 protein mutant form |
CTD |
PMID:15782132 PMID:18927120 |
|
NCBI chr11:32,387,775...32,435,539
Ensembl chr11:32,387,775...32,435,564
|
|
G |
XBP1 |
X-box binding protein 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [arsenite results in increased splicing of XBP1 mRNA] |
CTD |
PMID:22215663 |
|
NCBI chr22:28,794,560...28,800,569
Ensembl chr22:28,794,555...28,800,597
|
|
G |
XIAP |
X-linked inhibitor of apoptosis |
multiple interactions |
EXP |
Sirolimus promotes the reaction [Cisplatin results in decreased expression of XIAP protein] |
CTD |
PMID:18058806 |
|
NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,712...123,913,972
|
|
G |
YPEL1 |
yippee like 1 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein results in decreased expression of YPEL1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr22:21,697,536...21,735,794
Ensembl chr22:21,697,536...21,735,794
|
|
G |
YY1 |
YY1 transcription factor |
multiple interactions |
ISO |
Sirolimus inhibits the reaction [Glucose results in increased phosphorylation of YY1 protein] |
CTD |
PMID:35445903 |
|
NCBI chr14:100,239,144...100,282,788
Ensembl chr14:100,238,298...100,282,788
|
|
G |
ZIC2 |
Zic family member 2 |
multiple interactions |
EXP |
Sirolimus inhibits the reaction [TP73 protein affects the activity of ZIC2 protein] |
CTD |
PMID:21245298 |
|
NCBI chr13:99,981,784...99,986,765
Ensembl chr13:99,981,784...99,986,765
|
|
G |
ZNF628 |
zinc finger protein 628 |
decreases expression |
EXP |
Sirolimus results in decreased expression of ZNF628 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:55,476,617...55,484,487
Ensembl chr19:55,476,617...55,484,487
|
|
G |
ZWINT |
ZW10 interacting kinetochore protein |
multiple interactions |
EXP |
[fulvestrant co-treated with Sirolimus] results in decreased expression of ZWINT mRNA |
CTD |
PMID:19016759 |
|
NCBI chr10:56,357,227...56,361,273
Ensembl chr10:56,357,227...56,361,273
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects stability affects response to substance multiple interactions |
ISO EXP |
ABCB1A protein affects the stability of Everolimus ABCB1 polymorphism affects the susceptibility to Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCB1A protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCB1A protein affects the metabolism of irinotecan] |
CTD |
PMID:24727322 PMID:27169792 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
EXP |
Everolimus results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
affects stability multiple interactions |
ISO |
ABCG2 protein affects the stability of Everolimus bis(4-nitrophenyl)phosphate inhibits the reaction [ABCG2 protein affects the stability of Everolimus]; Everolimus inhibits the reaction [ABCG2 protein affects the metabolism of irinotecan] |
CTD |
PMID:24727322 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
AKT1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
EXP ISO |
Everolimus results in increased phosphorylation of AKT1 protein Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]] Everolimus results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16033851 PMID:22885370 PMID:23300809 PMID:28711525 PMID:37739323 |
|
NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,759
|
|
G |
AKT2 |
AKT serine/threonine kinase 2 |
multiple interactions increases phosphorylation |
ISO EXP |
Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT2 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT2 protein]] Everolimus results in increased phosphorylation of AKT2 protein |
CTD |
PMID:37739323 |
|
NCBI chr19:40,230,317...40,285,345
Ensembl chr19:40,230,317...40,285,536
|
|
G |
AKT3 |
AKT serine/threonine kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT3 protein]; MK 2206 inhibits the reaction [Everolimus inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT3 protein]] Everolimus results in increased phosphorylation of AKT3 protein |
CTD |
PMID:37739323 |
|
NCBI chr 1:243,488,233...243,851,079
Ensembl chr 1:243,488,233...243,851,079
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Everolimus inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:37739323 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
ISO |
Everolimus inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] |
CTD |
PMID:37739323 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression multiple interactions |
EXP |
Everolimus results in decreased expression of BIRC5 protein Everolimus promotes the reaction [platycodin D results in decreased expression of BIRC5 protein]; navitoclax promotes the reaction [Everolimus results in decreased expression of BIRC5 protein]; platycodin D promotes the reaction [Everolimus results in decreased expression of BIRC5 protein] |
CTD |
PMID:21601561 PMID:28711525 PMID:28947240 |
|
NCBI chr17:78,214,253...78,225,635
Ensembl chr17:78,214,186...78,225,636
|
|
G |
BRD4 |
bromodomain containing 4 |
multiple interactions |
EXP |
[MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] |
CTD |
PMID:25537515 |
|
NCBI chr19:15,235,519...15,332,539
Ensembl chr19:15,235,519...15,332,545
|
|
G |
CASP3 |
caspase 3 |
increases cleavage |
EXP |
Everolimus results in increased cleavage of CASP3 protein |
CTD |
PMID:15940265 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062
|
|
G |
CCNA2 |
cyclin A2 |
decreases expression |
EXP |
Everolimus results in decreased expression of CCNA2 protein |
CTD |
PMID:16856892 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCND1 |
cyclin D1 |
decreases expression multiple interactions |
EXP |
Everolimus results in decreased expression of CCND1 protein [letrozole co-treated with Everolimus] results in decreased expression of CCND1 protein |
CTD |
PMID:16033851 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCND2 |
cyclin D2 |
multiple interactions decreases expression |
EXP |
[letrozole co-treated with Everolimus] results in decreased expression of CCND2 protein Everolimus results in decreased expression of CCND2 protein |
CTD |
PMID:16033851 |
|
NCBI chr12:4,273,762...4,305,353
Ensembl chr12:4,269,771...4,305,353
|
|
G |
CCND3 |
cyclin D3 |
decreases expression |
EXP |
Everolimus results in decreased expression of CCND3 protein |
CTD |
PMID:16856892 |
|
NCBI chr 6:41,934,933...42,050,035
Ensembl chr 6:41,934,934...42,050,357
|
|
G |
CDH1 |
cadherin 1 |
increases expression |
EXP |
Everolimus results in increased expression of CDH1 protein |
CTD |
PMID:28258630 |
|
NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537
|
|
G |
CES1 |
carboxylesterase 1 |
decreases activity |
EXP |
Everolimus results in decreased activity of CES1 protein |
CTD |
PMID:24727322 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CES2 |
carboxylesterase 2 |
decreases activity |
EXP |
Everolimus results in decreased activity of CES2 protein |
CTD |
PMID:24727322 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CYCS |
cytochrome c, somatic |
multiple interactions |
ISO |
Everolimus inhibits the reaction [Doxorubicin results in increased expression of CYCS protein] |
CTD |
PMID:37739323 |
|
NCBI chr 7:25,118,656...25,125,260
Ensembl chr 7:25,118,656...25,125,260
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions increases expression |
EXP |
platycodin D inhibits the reaction [Everolimus results in increased expression of EGFR protein] Everolimus results in increased expression of EGFR mRNA; Everolimus results in increased expression of EGFR protein |
CTD |
PMID:28711525 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
EIF4E |
eukaryotic translation initiation factor 4E |
increases phosphorylation multiple interactions |
EXP |
Everolimus results in increased phosphorylation of EIF4E protein Everolimus inhibits the reaction [Estradiol results in decreased phosphorylation of EIF4E protein] |
CTD |
PMID:16033851 |
|
NCBI chr 4:98,879,276...98,929,133
Ensembl chr 4:98,879,276...98,929,133
|
|
G |
EIF4EBP1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases phosphorylation |
EXP |
[Letrozole co-treated with Everolimus] results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein]; Everolimus promotes the reaction [platycodin D results in decreased phosphorylation of EIF4EBP1 protein]; Everolimus results in increased phosphorylation of and results in decreased activity of EIF4EBP1 protein; platycodin D promotes the reaction [Everolimus results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:16033851 PMID:16856892 PMID:16951235 PMID:21372221 PMID:28711525 |
|
NCBI chr 8:38,030,534...38,060,365
Ensembl chr 8:38,030,534...38,060,365
|
|
G |
EIF4G1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions |
EXP |
Everolimus inhibits the reaction [Estradiol results in increased phosphorylation of EIF4G1 protein] |
CTD |
PMID:16033851 |
|
NCBI chr 3:184,314,606...184,335,358
Ensembl chr 3:184,314,495...184,335,358
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
Everolimus promotes the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:19567381 |
|
NCBI chr 1:94,529,173...94,541,759
Ensembl chr 1:94,529,173...94,541,759
|
|
G |
IGF1R |
insulin like growth factor 1 receptor |
increases expression multiple interactions |
EXP |
Everolimus results in increased expression of IGF1R mRNA; Everolimus results in increased expression of IGF1R protein platycodin D inhibits the reaction [Everolimus results in increased expression of IGF1R protein] |
CTD |
PMID:28711525 |
|
NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530
|
|
G |
ITGAM |
integrin subunit alpha M |
multiple interactions |
EXP |
Everolimus promotes the reaction [Tretinoin results in increased expression of ITGAM protein] |
CTD |
PMID:29743969 |
|
NCBI chr16:31,259,975...31,332,877
Ensembl chr16:31,259,967...31,332,892
|
|
G |
MAP1LC3A |
microtubule associated protein 1 light chain 3 alpha |
increases lipidation |
ISO |
Everolimus results in increased lipidation of MAP1LC3A protein |
CTD |
PMID:37739323 |
|
NCBI chr20:34,546,844...34,560,345
Ensembl chr20:34,546,854...34,560,345
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
Everolimus promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:32397857 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Everolimus inhibits the reaction [4-cresol results in increased expression of MMP9 protein] |
CTD |
PMID:30910523 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
MTOR |
mechanistic target of rapamycin kinase |
multiple interactions decreases phosphorylation decreases activity |
EXP ISO |
[Everolimus co-treated with Y 27632] inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; [Letrozole co-treated with Everolimus] inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [4-cresol results in increased phosphorylation of MTOR protein]; Everolimus inhibits the reaction [Androstenedione affects the activity of MTOR protein]; Everolimus inhibits the reaction [Estradiol affects the activity of MTOR protein]; Everolimus inhibits the reaction [MTOR results in decreased susceptibility to Trabectedin] Everolimus results in decreased phosphorylation of MTOR protein Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]] Everolimus results in decreased activity of MTOR; Everolimus results in decreased activity of MTOR protein |
CTD |
PMID:16033851 PMID:20890178 PMID:21622721 PMID:24989011 PMID:30910523 PMID:37739323 More...
|
|
NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases response to substance increases expression |
EXP |
[MYC protein results in decreased susceptibility to Everolimus] promotes the reaction [BRD4 protein binds to MYC gene] Everolimus results in increased expression of MYC protein |
CTD |
PMID:25537515 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NGF |
nerve growth factor |
multiple interactions |
ISO |
Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of MTOR protein]]; Everolimus inhibits the reaction [rhodioloside inhibits the reaction [[cobaltous chloride co-treated with NGF protein] results in decreased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:24989011 |
|
NCBI chr 1:115,285,917...115,338,249
Ensembl chr 1:115,285,904...115,338,770
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
EXP |
Aspirin inhibits the reaction [Everolimus results in decreased expression of NOS3 protein]; Cilostazol inhibits the reaction [Everolimus results in decreased expression of NOS3 protein] |
CTD |
PMID:19520256 |
|
NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
decreases activity |
ISO |
Everolimus results in decreased activity of NR1I3 protein |
CTD |
PMID:30203046 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
[navitoclax co-treated with Everolimus] results in increased cleavage of PARP1 protein |
CTD |
PMID:28947240 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Everolimus results in increased expression of PTGS2 mRNA; Everolimus results in increased expression of PTGS2 protein |
CTD |
PMID: |